The mechanism and manipulation of PK-M alternative splicing by Wang, Zhenxun
 
 
 
The mechanism and manipulation of PK-M alternative splicing 
      
 
                          
 
 
 
 
 
 
        
 
                                                                 Thesis Dissertation 
 
            By 
                        Zhenxun Wang 
 
                      Watson School of Biological Sciences, Cold Spring Harbor Laboratory 
 
 
 
      Advisor: Dr. Adrian R. Krainer  
 
      December  2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
TABLE OF CONTENTS 
  
1 CHAPTER 1: INTRODUCTION...................................................................................................................... 5 
1.1 SPLICING AND ITS IMPORTANCE IN GENE EXPRESSION .................................................................................. 5 
1.2 CANONICAL SPLICING CIS-ELEMENTS ............................................................................................................ 5 
1.3 THE MOLECULAR MECHANISM OF SPLICING .................................................................................................. 6 
1.4 SPLICING IS LINKED TO THE DOWNSTREAM STEPS OF GENE EXPRESSION..................................................... 7 
1.5 ALTERNATIVE SPLICING IS A MAJOR SOURCE OF PROTEOMIC DIVERSITY IN EUKARYOTES ......................... 8 
1.6 TYPES OF ALTERNATIVE SPLICING OUTCOMES .............................................................................................. 9 
1.7 MECHANISMS OF ALTERNATIVE SPLICING: SPLICING CIS ELEMENTS............................................................ 9 
1.8 TRANS MEDIATORS OF ALTERNATIVE SPLICING ........................................................................................... 10 
1.9 MECHANISMS OF ACTIVATION ..................................................................................................................... 10 
1.10 MECHANISMS OF REPRESSION.................................................................................................................... 11 
1.11 POSITIONAL DEPENDENCE OF SPLICING FACTORS ON SPLICING OUTCOMES............................................. 12 
1.12 EMERGING MODELS OF SPLICING REGULATION......................................................................................... 13 
1.13 MECHANISTIC QUESTIONS IN MUTUALLY EXCLUSIVE SPLICING............................................................... 14 
1.14 ALTERED SPLICING IN CANCER .................................................................................................................. 15 
1.15 SR PROTEINS IN CANCER ............................................................................................................................ 16 
1.16 THE WARBURG EFFECT AND TUMORIGENESIS........................................................................................... 16 
1.17 ONCOGENES AND THE WARBURG EFFECT ................................................................................................. 17 
1.17.1 Phosphatidylinositol 3-kinase signaling pathway ........................................................................... 17 
1.17.2 Oncogenic transcription factors ....................................................................................................... 17 
1.18 PYRUVATE KINASE ISOFORMS AND THE WARBURG EFFECT ..................................................................... 18 
1.19 INHIBITION OF PKM2 KINASE ACTIVITY IS IMPORTANT FOR THE WARBURG EFFECT ............................. 19 
1.20 ALTERNATIVE SPLICING OF THE PKM GENE ............................................................................................. 20 
1.21 PRELIMINARY ANALYSES OF THE PK-M GENE.......................................................................................... 21 
1.22 PK-M EXON 9 REPRESSION IN TUMOR CELLS ........................................................................................... 21 
1.23 CRITICAL CIS-ELEMENTS AND THE QUESTION OF EXON 10 DEFINITION................................................... 22 
1.24 SPLICING ANTISENSE OLIGONUCLEOTIDES ............................................................................................... 22 
1.25 ASO-MEDIATED SPLICING CORRECTION IN DISEASE................................................................................. 23 
1.26 APPLICATION OF SPLICING ASO TECHNOLOGY TO PKM2 SPLICING IN CANCER CELLS ......................... 25 
2 CHAPTER 2: EXON-CENTRIC REGULATION OF PYRUVATE KINASE M ALTERNATIVE 
SPLICING VIA MUTUALLY EXCLUSIVE EXONS ....................................................................................... 26 
2.1 MANUSCRIPT AND CONTRIBUTIONS ............................................................................................................ 27 
2.2 ABSTRACT..................................................................................................................................................... 27 
2.3 INTRODUCTION ............................................................................................................................................. 28 
2.4 RESULTS........................................................................................................................................................ 31 
2.4.1 A PK-M minigene recapitulates alternative splicing of the endogenous gene ................................ 31 
2.4.2 Blocking exon 10 inclusion does not fully rescue exon 9 inclusion.................................................. 32 
2.4.3 Strengthening the splice sites of exon 9 leads to aberrant PK-M splicing....................................... 33 
2.4.4 Exonic splicing silencers and enhancers are key determinants of PK-M splicing ratios ............... 34 
2.4.5 A strong ESE in exon 10 is necessary and sufficient for activation of the exon .............................. 36 
2.4.6 SRSF3 binds specifically to the exon-10 ESE .................................................................................... 37 
2.4.7 SRSF3 is necessary for exon 10 inclusion.......................................................................................... 38 
2.4.8 SRSF3 affects endogenous PK-M splicing ......................................................................................... 39 
2.4.9 SRSF3 activates endogenous PK-M exon 10 ..................................................................................... 39 
2.4.10 SRSF3 is necessary for aerobic glycolysis and cellular proliferation ........................................... 40 
2.5 DISCUSSION................................................................................................................................................... 41 
2.6 EXPERIMENTAL PROCEDURES...................................................................................................................... 46 
2.6.1 Cells and transfections ........................................................................................................................ 46 
2.6.2 RNA interference.................................................................................................................................. 46 
2.6.3 Immunoblotting .................................................................................................................................... 46 
 3 
2.6.4 Plasmids ............................................................................................................................................... 47 
2.6.5 RT-PCR................................................................................................................................................. 48 
2.6.6 RNA-affinity chromatography and mass spectrometry ..................................................................... 49 
2.6.7 Lactate assay ........................................................................................................................................ 49 
2.6.8 MTT assay ............................................................................................................................................ 50 
2.7 SUPPLEMENTARY EXPERIMENTAL PROCEDURES ........................................................................................ 51 
2.8 FIGURES AND FIGURE LEGENDS................................................................................................................... 58 
2.8.1 Figure 1. Detection of endogenous and minigene-specific PK-M spliced isoforms........................ 58 
2.8.2 Figure 2. Effects of splice-site relative strengths on inclusion of exon 9......................................... 61 
2.8.3 Figure 3. Effects of exonic cis-elements on PK-M alternative splicing ........................................... 63 
2.8.4 Figure 4. Mapping an ESE in exon 10 ............................................................................................... 66 
2.8.5 Figure 5. SRSF3 binds to the motif in exon 10 and is necessary for exon 10 inclusion ................. 68 
2.8.6 Figure 6. SRSF3 affects endogenous levels of PK-M1/M2, aerobic glycolysis, and cellular 
proliferation....................................................................................................................................................... 71 
2.8.7 Figure 7. Regulation of PK-M splicing in cancer cells ..................................................................... 73 
2.8.8 Supplementary Figure 1. Diagram of PK-M minigene-specific RNA species in Figs. 1-4. ............ 75 
2.8.9 Supplementary Figure 2. The splice sites of exons 9 and 10 play only a minor role in PK-M 
alternative splicing ........................................................................................................................................... 77 
2.8.10 Supplementary Figure 3. Codon and conservation analysis of PK-M exons 9 and 10................. 79 
2.8.11 Supplementary Figure 4. Western blots for overexpression and knockdown experiments in 
Figure 6.............................................................................................................................................................. 81 
2.8.12 Supplementary Figure 5. SRSF3 does not repress splicing of exon 9. ........................................... 83 
3 CHAPTER 3 ....................................................................................................................................................... 84 
RESCUE OF PK-M EXON 9 INCLUSION BY ANTISENSE OLIGONUCLEOTIDES TARGETING 
PK-M IN CANCER CELLS.................................................................................................................................... 84 
3.1 INTRODUCTION ............................................................................................................................................. 85 
3.2 RESULTS........................................................................................................................................................ 88 
3.2.1 An exon-centered ASO screen uncovers potent oligonucleotides that increase PK-M1 inclusion in 
cancer cells ........................................................................................................................................................ 88 
3.2.2 The G7 ASO targets a novel activation region of PK-M exon 10..................................................... 89 
3.2.3 The G7 ASO interferes with exon 10 definition ................................................................................. 89 
3.2.4 The second binding site for the G7 ASO is located in PK-M intron 9. ............................................ 90 
3.2.5 The exon 10 G7 region is more important for ASO-mediated PK-M1 inclusion............................. 91 
3.2.6 G7 ESE region centered ASO microwalks ......................................................................................... 92 
3.2.7 ASOs targeting the exon 10 G7 region induce apoptosis in glioblastoma cells. ............................. 92 
3.2.8 ASO-mediated apoptosis is caused by the downregulation of endogenous PK-M2 expression in 
glioblastoma cells.............................................................................................................................................. 94 
3.3 DISCUSSION................................................................................................................................................... 95 
3.3.1 Apoptotic effects of PK-M2 isoform switching in glioblastoma cells............................................... 95 
3.3.2 Translational inhibition of PK-M2 mRNA ......................................................................................... 96 
3.3.3 Mechanism of ASO-mediated PK-M2 to PK-M1 switch ................................................................... 96 
3.3.4 Failure of exon 9 ASOs to rescue PK-M1 inclusion.......................................................................... 97 
3.3.5 Use of ASOs in mouse models of glioblastoma.................................................................................. 97 
3.4 EXPERIMENTAL PROCEDURES...................................................................................................................... 98 
3.4.1 Cells and transfections ........................................................................................................................ 98 
3.4.2 Oligonucleotide synthesis .................................................................................................................... 98 
3.4.3 RNA interference.................................................................................................................................. 98 
3.4.4 Retrovirus transduction ....................................................................................................................... 99 
3.4.5 Immunoblotting .................................................................................................................................... 99 
3.4.6 Minigene construction ....................................................................................................................... 100 
3.4.7 RT-PCR............................................................................................................................................... 103 
3.5 FIGURE LEGENDS........................................................................................................................................ 105 
3.5.1 Fig 1. Initial ASO walk along PK-M exon 10. ................................................................................. 106 
3.5.2 Fig 2. Initial ASO walk along PK-M exon 9. ................................................................................... 108 
 4 
3.5.3 Fig 3. Characterizing the G7 ASO target region............................................................................. 110 
3.5.4 Fig 4 A second binding site for G7 ASO. ......................................................................................... 113 
3.5.5 Fig 5. G7-centered ASO microwalks. ............................................................................................... 115 
3.5.6 Fig 6. Effects of ASOs on glioblastoma cells. .................................................................................. 117 
4 CHAPTER 4. CONCLUSIONS AND PERSPECTIVES .......................................................................... 118 
4.1 SUMMARY OF CONCLUSIONS ...................................................................................................................... 118 
4.2 FUTURE DIRECTIONS................................................................................................................................... 118 
4.2.1 Analysis of PK-M splicing in a PK-M1 dominant system ............................................................... 118 
4.2.2 Uncovering exon 9 ESSs.................................................................................................................... 119 
4.2.3 Prevention of exon 9 and exon 10 double splicing .......................................................................... 119 
4.2.4 Effects of transcription and signaling pathways on PK-M splicing ............................................... 120 
4.2.5 Tissue-specific mechanisms of PK-M splicing ................................................................................. 120 
4.2.6 Establishment of in vitro splicing system to find trans-acting factors involved in PK-M splicing
 121 
4.3 FIGURES AND LEGENDS .............................................................................................................................. 122 
4.3.1 Fig 1. Unpublished data and future directions. ............................................................................... 123 
5 LIST OF ABBREVIATIONS......................................................................................................................... 124 
6 APPENDIX: BIBLIOGRAPHY .................................................................................................................... 126 
  
TABLE OF FIGURES 
FIGURE 2.8-1 ................................................................................................................................................................ 58 
FIGURE 2.8-2 ................................................................................................................................................................ 61 
FIGURE 2.8-3 ................................................................................................................................................................ 63 
FIGURE 2.8-4 ................................................................................................................................................................ 65 
FIGURE 2.8-5 ................................................................................................................................................................ 67 
FIGURE 2.8-6 ................................................................................................................................................................ 70 
FIGURE 2.8-7 ................................................................................................................................................................ 72 
FIGURE 2.8-8 ................................................................................................................................................................ 74 
FIGURE 2.8-9 ................................................................................................................................................................ 76 
FIGURE 2.8-10 .............................................................................................................................................................. 78 
FIGURE 2.8-11 .............................................................................................................................................................. 80 
FIGURE 2.8-12 .............................................................................................................................................................. 82 
FIGURE 3.5-1 .............................................................................................................................................................. 105 
FIGURE 3.5-2 .............................................................................................................................................................. 107 
FIGURE 3.5-3 .............................................................................................................................................................. 109 
FIGURE 3.5-4 .............................................................................................................................................................. 112 
FIGURE 3.5-5 .............................................................................................................................................................. 114 
FIGURE 3.5-6 .............................................................................................................................................................. 116 
FIGURE 4.3-1 .............................................................................................................................................................. 122 
 
 
 5 
 
1 CHAPTER 1: INTRODUCTION
 
1.1 Splicing and its importance in gene expression 
Pre-mRNA splicing involves the precise excision of intervening RNA sequences known as 
introns, and the joining of flanking coding sequences, known as exons, during or 
immediately after the transcription of primary mRNA (Black, 2003). This process is 
widespread and is considered to be an obligate step for the expression of the vast majority of 
human genes. An analysis of all annotated human genes revealed that the transcribed genome 
consists of approximately 230000 exons and 210000 introns, roughly nine exons and eight 
introns per gene (Sakharkar et al., 2004). 
 
 
1.2 Canonical splicing cis-elements 
Exon-intron junctions on the pre-mRNA are demarcated by specific sequence motifs. The 
motifs are conserved yet degenerate, and consist of the branchpoint sequence (BPS), the 5’ 
splice site (5’ss) and the 3’ splice site (3’ss). The BPS is typically present 18-40 nucleotides 
upstream from the 3’ss (Will and Luhrmann 2011), and a polypyrimidine-rich tract (PPT) lies 
between both. These splicing elements are necessary for splicing of the pre-mRNA, and 
serve as binding sites for the step-wise recruitment and assembly of spliceosomal 
components, which carry out the actual splicing reaction.
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1.3 The molecular mechanism of splicing 
The spliceosome is a nuclear macromolecular complex consisting of small RNAs and 
proteins. Individual small RNA-protein complexes, termed small nuclear ribonuclear proteins 
(snRNPs) are sequentially recruited to exon-intron junctions by binding the canonical 
splicing elements present on the pre-mRNA (Hastings and Krainer, 2001).  
The U1, U2, U4/U6 and U5 snRNPs are the main components of the spliceosome and 
are involved in the removal of most introns in the eukaryotic genome. In some metazoans 
and plants, a second, minor spliceosome, which consists of the U11/U12, U4atac/U6atac, and 
U5 snRNPs, is needed to process the rarer U12-class of introns (Patel and Steitz, 2003). 
Although minor spliceosome snRNP components recognize different splice sites and BPS 
sequences, they are analoglous to the major spliceosome in function, with the U5 snRNP 
being used by both kinds of spliceosomes.  
These snRNPs have been characterized intensely in vitro and it has been found that 
the stepwise assembly and intramolecular rearrangements of snRNPs on the pre-mRNA are 
required to render the spliceosomal complex catalytically active and competent to perform 
the actual splicing reaction (Will and Luhrmann, 2011). Initial recognition of the intron-exon 
junctions occurs through the recruitment of U1 snRNP to the 5’ss via RNA:RNA 
interactions; protein components associated with the U2 snRNP bind to the BPS and 3’ss at 
the same time, forming the E complex. The A complex is formed when the U2 snRNA base-
pairs with the BPS evicting the initially bound SF1 protein in the E complex. The U4/U6 and 
U5 tri-snRNP complex is then recruited to the B complex. The B complex is then rendered 
catalytically active through a series of arrangements that includes the eviction of U1 and U4 
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snRNPs forming the C complex, and it then carries out the first transesterification step of the 
splicing reaction,  
In the first step, the 2’OH group of the adenosine branchpoint nucleotide attacks the 
phosphodiester bond of the 5’ss, cleaving it and ligating the 5’end of the intron to the 
adenosine, forming a lariat. Additional rearragements then occur, which render the 
spliceosome competent to carry out the second transesterification step. 
In the second step, the free 3’OH group of the upstream exon attacks the 3’ss, 
forming a new phosphodiester bond that joins both exons, with the simultaneous removal of 
the intron lariat. After this step, the spliceosome dissociates, releasing the mRNA as an 
mRNP. The free snRNPs then reassembles elsewhere in the nascent pre-mRNA to carry out 
splicing reactions.  
Although the details of snRNP rearrangements in the later steps of splicing are poorly 
understood, note that all rearrangements involve numerous individually weak RNA:protein 
and RNA:RNA interactions. These interactions collectively stabilize the spliceosomal 
complex, allowing it recognize degenerate splice signals with great fidelity, and catalyze the 
splicing reaction with great flexibility, even at long (>10 kb) intronic distances, in a regulated 
manner.
1.4 Splicing is linked to the downstream steps of gene expression 
Splicing effector proteins that mediate post-transcriptional processes are usually 
deposited on the mature mRNA in a splicing-dependent manner (Moore and Proudfoot, 
2009). This allows splicing to be coupled to these processes (Long and Caceres, 2009), 
which include mRNA export (Huang and Steitz, 2005), translation (Michlewski et al., 2008), 
and surveillance of premature stop codons by the nonsense-mediated decay machinery 
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(NMD) (McGlincy and Smith, 2008; Zhang and Krainer, 2004). In particular, the exon-
junction (EJC) protein complex was found to be stably deposited on spliced mRNA about 20-
24 nucleotides upstream of exon-exon junctions (Le Hir et al., 2000), where it participates in 
mRNA surveillance. The EJC complex accompanies the mRNA as it is transported into the 
cytoplasm, where it is removed by during the pioneer round of translation. In the event that a 
premature stop codon is present more than 50 nucleotides upstream of an EJC on the mRNA 
the EJC complex is not removed from the mRNA and this induces the recruitment of RNA 
decay machinery that leads to the inhibition of translation of, and to the eventual degradation 
of the transcript (Chang et al., 2007; Stalder and Muhlemann, 2008).
 
1.5 Alternative splicing is a major source of proteomic diversity in eukaryotes 
By differentially splicing exons or exon segments from pre-mRNA, multiple mature 
mRNAs can be generated from the same pre-mRNA transcript (Black, 2003; Matlin et al., 
2005). This process, known as alternative splicing, is a major source of protein isoform 
diversity in mammals (Black, 2000). An analysis of tissue-specific splicing via exon-junction 
micrarrays revealed that 74% of more than 10000 genes analyzed encode transcripts that 
result in multiple spliced isoforms (Johnson et al., 2003). Recent RNA deep-sequencing 
experiments also confirm and extend this analysis, estimating that nearly all (92% -95%) 
multi-exon genes undergo alternative splicing (Pan et al., 2008; Wang et al., 2008). Protein 
isoforms resulting from these alternatively spliced variants often have distinct or even 
antagonistic functions (Black, 2003; Cartegni et al., 2002; Matlin et al., 2005). 
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1.6 Types of alternative splicing outcomes 
Alternative splicing outcomes are generally divided into 5 types (reviewed in (Black, 2003; 
Cartegni et al., 2002): 
1. Use of alternative 5’ or 3’ splice sites, usually located near each other. This leads to a 
lengthening or shortening of an exon. 
2. Alternative use of a promoter or a polyadenylation (poly(A)) site. This affects the 5’ or 3’ 
composition of a mature mRNA 
3. Retention of an intron. 
4. Cassette exons. The most commonly observed alternative splicing system in global 
genomic analyses (Pan et al., 2008; Wang et al., 2008), where a exon could be included or 
excluded, depending on the outcome of the competition between factors that activate or 
repress this exon. 
5. Mutually exclusive exons. This is where only a single exon is selected from a pair, or an 
array of competing exons.
1.7 Mechanisms of alternative splicing: splicing cis elements 
Although the canonical splicing elements are necessary for splicing to occur, they are not 
sufficient to specify alternatively spliced (AS) exons. Inclusion or exclusion of AS exons is 
thus regulated through an additional set of specific cis-regulatory elements – exonic or 
intronic splicing enhancers (ESE, ISE) and silencers (ESS, ISS) present on the pre-mRNA. 
This is because alternatively spliced exons tend to have weaker splice sites that deviate from 
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the consensus (Roca et al., 2005). This permits the regulation of alternative splicing through 
these motifs by binding cognate trans-acting factors in a combinatorial fashion to promote or 
inhibit the recruitment of spliceosomal machinery, resulting in the respective enhancement or 
suppression of splicing (Black, 2003). Note that splicing cis-element also contribute to the 
definition of constitutive exons through similar mechanisms. 
 
1.8 Trans mediators of alternative splicing 
The trans-acting factors that regulate alternative splicing are typically RNA-binding 
proteins, a subset of which are classified into two groups: the Ser/Arg-rich (SR) proteins 
(Graveley, 2000) and heterogeneous ribonucleoproteins (hnRNP), which generally recognize 
enhancers and silencers, respectively. Reflecting their function, both classes of proteins 
typically contain one or two RNA recognition motifs (RRM) and a domain that is involved in 
interactions with other trans-acting factors and/or spliceosomal components. SR and hnRNP 
proteins typically have opposing effects on the alternative splicing of exons, eliciting changes 
in splicing outcomes in a concentration-dependent manner (Black, 2003). Consequently, non-
physiological changes in the global levels of SR and hnRNP proteins can potentially alter the 
splicing profile of cells and lead to aberrant splicing of multiple target genes. 
 
1.9 Mechanisms of activation 
The mechanistic basis of SR-protein mediated splicing activation has been well 
defined and can be reasonably applied to any other class of splicing activators. Splicing 
factor activation is thought to work in two modes. 
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Splicing factors that are bound to a enhancer element work to recruit spliceosomal 
components to weak 5’ or 3’ss. For example, a SR protein bound to an exonic splicing 
enhancer typically activates the splicing of its cognate exon by stabilizing the interaction of 
the U2AF splicing factor, which is part of the U2 snRNP, with a weak 3’ss and/or BPS via its 
RS interaction domain (Graveley et al., 2001; Zuo and Maniatis, 1996). The same factor 
could also perform the same function by stabilizing U1 snRNP interactions with a 
downstream 5’ss, or through indirect interactions with a splicing co-activator such as 
Srm160, stabilize and recruit U1 snRNPs to the upstream 5’ss (Eldridge et al., 1999). In the 
intronic context, TIA1 binding to a downstream ISE in the FAS transcript activates the 
upstream exon by facilitating the recruitment of U1 snRNP to the upstream 5’ss (Matlin et 
al., 2005). 
The second mode of activation involves antagonizing splicing repressor function by 
binding to a splicing enhancer site in the proximity of the silencer site. This mode explains 
the observations that the recruitment of a SR protein to an ESE is sufficient for splicing 
activation, even in the absence of a RS interaction domain (Kan and Green, 1999; Zhu et al., 
2001).
 
1.10 Mechanisms of repression 
As with SR proteins, the best-known mechanisms of repression come from 
mechanistic analysis of hnRNP-mediated splicing repression. In the first mode, a hnRNP 
protein binding to a splicing silencing site that is in the proximity of an splicing enhancer site 
antagonizes splicing activator function, destabilizing spliceosomal assembly on the pre-
mRNA (Zhu et al., 2001). In the second mode, the splicing repressor binds to a high affinity 
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silencing element, inducing the cooperative binding of the same or additional inhibitory 
factors, eventually spreading across the exons and splice sites. This inhibits the recruitment 
to splicing activators to splicing enhancer sites and/or blocks the recruitment of spliceosomal 
components to splice sites. In the third mode, two splicing repressors are recruited to distant 
intronic silencer sites, and then dimerize, bringing the two sites in close proximity 
(Blanchette and Chabot, 1999; Wagner and Garcia-Blanco, 2001). This causes the 
intervening RNA sequence to be looped out and not be recognized by the splicing machinery. 
 
1.11 Positional dependence of splicing factors on splicing outcomes 
Recent genome-wide analysis of splicing factors through the isolation and deep 
sequencing of RNA that are UV-crosslinked to RNA binding proteins (Cross Linking and 
Immunoprecipitation-sequencing experiments, or CLIP-seq), combined with RNA-
sequencing experiments or splicing micro-array data that correlate splicing factor-RNA 
interactions with splicing outcomes has generated RNA splicing maps that bring new insights 
on the positional dependence of splicing factors that influence splicing outcomes (Licatalosi 
and Darnell, 2010). For example, a variety of splicing factors, for example, Polypyrimidine 
tract binding protein (PTB) (Xue et al., 2009) and Nova (Licatalosi et al., 2008) splicing 
factors repress exon inclusion by binding at positions close to canonical splice sites or within 
exons, but activate exon inclusion when bound downstream of exons. It has also been found 
that splicing factors also exert their effects on distal exons; for example, the splicing factor 
TIA1 has been demonstrated to silence inclusion of downstream alternatively-spliced exons 
when bound near the 5’ss of preceding exons (Wang et al., 2010). A mechanistic basis of 
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these observations has not been elucidated thus far, but most likely requires a rethinking of 
the above-mentioned classical splice site competition mechanisms. 
 
1.12 Emerging models of splicing regulation 
There are two main models of splicing regulation that could explain the positional 
dependent effects of splicing factors, which are not mutually exclusive. Both take into 
account the observations that transcriptional elongation and chromatin affect splicing. In the 
recruitment model, the C terminal domain (CTD) of RNA polymerase II and local chromatin 
architecture recruit specific splicing factors to nascent RNA. In support of this hypothesis, it 
has been observed that recruitment of SR proteins to RNA is CTD dependent, and that 
antibodies against CTD also coimmunoprecipitate SR proteins (Caceres and Kornblihtt, 
2002). Specific modifications of histone H3 have also been demonstrated to bind PTB (Luco 
et al., 2010). The specific position-dependent outcome of splicing factors could thus depend 
on specific, local, extra-RNA variables such as promoter identity, post-translational 
modifications to the CTD, and histone modifications (Luco et al., 2011) that recruit a specific 
repertoire of factors that influences a splicing decision. However, since splicing decisions 
depend on combinatorial outputs, how much of a role these extra-RNA variables play in 
influencing a splicing outcome of a particular exon remains to be seen. 
In the second model, it is postulated that splicing factors binding to distal sites could 
affect the kinetics of spliceosomal assembly from the E to C complexes (Witten and Ule, 
2011) . In particular, a decrease in the rate of spliceosomal assembly at an upstream splice 
site could allow more time for a downstream splice site to recruit splicing enhancers that 
activate the downstream exon. In support of this model, expression of a slow RNA pol II 
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mutant leads to an increased usage of an upstream 5’ ss in the Adenovirus E1a splicing 
system as the slower elongation of RNA pol II presumably leads to a slower spliceosomal 
assembly at the 5’ss, allowing a longer window for splicing factor mediated use of the 5’ss 
(de la Mata et al., 2003). Similarly in the example of TIA, recruitment of TIA to the upstream 
5’ss could accelerate the rate of spliceosomal assembly at the 5’ss, decreasing the window of 
time for splicing factors to stabilize U2 snRNP interaction at the downstream 3’ss of the 
downstream exon, leading to suppression of exon inclusion (Wang et al., 2010). However, 
the exact mechanism by which these splicing factors affect spliceosomal assembly remains to 
be elucidated. 
 
1.13 Mechanistic questions in mutually exclusive splicing 
Mutually exclusive splicing by definition mandates the selection of only one exon out 
of an array of two or more exons. Two major questions are then evident in a mutually 
exclusive splicing system. 1) What prevents two mutually exclusive exons from being 
spliced together? 2) How is one exon preferentially included over the other? Four 
mechanisms have been proposed for the first question (Smith, 2005). The first is that there 
are minimum spacing requirements (~50 bps) between the 5’ss and BPS in the introns for 
splicing. Below this threshold, steric interference prevents the complete spliceosome 
complex from being recruited to the intron and for splicing to occur. The second is that 
inclusion of both exons leads to altering of the reading frame and the introduction of 
premature stop codons (PTC) in the transcript, leading to degradation of the transcript by 
NMD. The third is splice site incompatibility. The consensus splice sites recognized by the 
minor spliceosome are different from those of the major spliceosome, such that an intron 
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with a U11 5’ss and a U2 3’ss (or vice versa) cannot be spliced. This has been observed in 
intron 6 of the mutually exclusive exons 6 and 7 in the JNK gene. The last mechanism 
involves the formation of long-distance intramolecular secondary structures (Graveley, 2005; 
Kreahling and Graveley, 2005; May et al., 2011; McManus and Graveley, 2011; Olson et al., 
2007). This has been observed in Drosophila through the comparison of conserved sequences 
present around the mutually exclusive exon 6 cluster of exons. These exons were found to be 
constitutively repressed, but exon selection requires the pairing of a selector site sequence 
found upstream of each exon with a doctor site found in intron 5 between the constitutive 
exon 5 and the first ME exon in the exon 6 cluster. Mutations in the docking site lead to the 
complete skipping of the exon 6 cluster, while mutations of the selector site that weakened or 
strengthened the base pairing interactions between these two sites decreased or increased the 
inclusion of the particular exon, respectively (May et. al. 2011). Although this mode of ME 
maintenance has been well characterized in Drosophila DSCAM, it remains to be seen 
whether similar intramolecular base pairing-mediated exon selection mechanisms could 
occur in other splicing systems.
 
1.14 Altered splicing in cancer 
Since alternative splicing often modulates the activities of oncogenes and tumor 
suppressors, aberrant splicing is strongly correlated with cancer. This happens either through 
mutations that change cis-acting splicing sequences in genes, or through changes in levels of 
splicing regulators in cells. In the former, mutations that affect the alternative splicing of 
tumor suppressors, such as BRCA1/2 (Venkitaraman, 2002), WT1 (Hammes et al., 2001), 
LKB1 (Hastings et al., 2005), APC, TP73, and TSC1/2 (Venables, 2004) account for sporadic 
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or hereditary susceptibility to cancer. In the latter case, aberrant expression of SR proteins 
has been implicated in tumorigenesis (Fischer et al., 2004; Ghigna et al., 2005; He et al., 
2004).
  
1.15 SR proteins in cancer 
In particular the prototypical SR protein SRSF1 was recently found to be highly 
expressed in a variety of tumor samples. Overexpression of SRSF1 in vitro was sufficient to 
transform immortal rodent fibroblasts by altering splicing in a number of key genes involved 
in apoptosis and metabolism, including a dominant-negative form of the apoptosis mediator 
protein, BIN1 (Ge et al., 1999; Sakamuro et al., 1996), and a novel, oncogenic isoform of a 
key regulator of global protein translation, RPS6KB1.  
Similar to its paralog SRSF1, SRSF3 has also been implicated in tumorigenesis. 
SRSF3 is overexpressed in ovarian cancers (He et al., 2004) and cervical cancer cell lines, 
whereas in normal cervical tissue its expression is restricted to the basal proliferating layers 
(Jia et al., 2009). SRSF3 is also a downstream target of the oncogenic β-catenin/TCF-4 
pathway in colorectal cancer cells (Goncalves et al., 2008). Moreover, overexpression of 
SRSF3 was recently found to be sufficient for transformation of NIH-3T3 immortal mouse 
fibroblasts (Jia et al., 2010). 
 
1.16 The Warburg effect and tumorigenesis 
When Warburg observed that cancer cells exhibited a high rate of glycolysis and 
produced lactic acid avidly even under aerobic conditions, he proposed that cancer was 
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initiated through the impairment of oxidative phosphorylation (Warburg, 1956). Although 
this hypothesis has since been discredited, the plethora of oncogenes (see below) that 
maintain and reinforce the “Warburg effect” - the metabolic switch from oxidative 
phosphorylation to aerobic glycolysis - implies that this event is undoubtedly important.
 
1.17 Oncogenes and the Warburg effect
1.17.1 Phosphatidylinositol 3-kinase signaling pathway  
  
This signaling pathway connects upstream growth factor signaling pathways to 
downstream pathways that mediate cellular growth and survival. As such, constitutive 
activation of this pathway is a common feature in cancers (Cairns et al., 2011). The 
downstream effector of PI3K, AKT1, is an important mediator of tumor glycolysis. It 
stimulates glycolysis by stimulating glucose uptake and activating rate-limiting glycolytic 
enzymes (Elstrom et al., 2004). AKT also stimulates anabolic metabolism by activating the 
mammalian target of rapamycin (mTOR) kinase (Robey and Hay, 2009), which controls 
global mRNA translation and ribosome biogenesis (Guertin and Sabatini, 2007). 
1.17.2 Oncogenic transcription factors 
  
The oncogene Myc plays an important role in controlling cell cycle and 
differentiation. Together with Hypoxia-inducible factor 1 (HIF1α), it also stimulates 
glycolysis by directly upregulating the expression of glyolytic enzymes, including the 
pyruvate kinases (PK-M, PK-R, PK-L)  and glucose transporters (Dang et al., 2008; 
Semenza, 2010). Crucially, HIF1 also activates the expression of pyruvate dehydrogenase 
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kinase 1 (PDK1), which shunts pyruvate away from the mitochondrial oxidative 
phosphorylation pathways (Kim et al., 2006; Papandreou et al., 2006). In normal oxygen 
conditions, HIF1 undergoes an oxygen-dependent hydroxylation on its α-subunit that results 
in its ubiquitination by the von Hippel-Lindau tumor suppressor, and is subsequently 
degraded (Kaelin, 2008). As a result, HIF1 is only stabilized in hypoxic conditions, but it is 
constitutively stabilized in normal oxygen conditions in cancer cells due to activated 
oncogenic signaling pathways, including PI3K, or through the inactivation of tumor 
suppressors involved in its destabilization (Cairns et al., 2011). 
 
1.18 Pyruvate kinase isoforms and the Warburg effect 
What advantages does aerobic glycolysis confer to transformed cells? Recent studies 
by Christofk and colleagues  illuminate a possible raison d'être for the Warburg effect: 
conferring a proliferative advantage by facilitating anabolic metabolism (Christofk et al., 
2008a; Christofk et al., 2008b). 
Pyruvate kinase is a key rate-limiting enzyme in the glycolytic pathway that is tightly 
regulated in cells  and catalyzes the conversion of its substrate phosphoenolpyruvate (PEP) to 
pyruvate (Mazurek et al., 2005). The pyruvate kinase-m (PK-M) gene encodes two splice 
isoforms that differ by the inclusion of one of two mutually exclusive exons.  The authors 
first discovered that in mouse and human tumor samples, expression of the fetal M2 isoform, 
together with the concurrent downregulation of the adult M1 isoform, correlated with tumor 
development. A further screen of established cancer cell lines using isoform-specific 
antibodies confirmed this correlation. They then knocked down endogenous PKM2 by RNAi 
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in cancer cell lines and re-expressed mouse versions of either PKM2 or PKM1 and compared 
their metabolic and proliferation profiles. 
Although PKM1 and PKM2-expressing cells were indistinguishable under normoxic 
conditions, strong differences were observed in hypoxia. M2-expressing cells grew at a 
higher rate, consumed less oxygen, and produced more lactate than M1 cells, all of which are 
hallmarks of the Warburg effect. Strikingly, ATP levels in both cell lines under either normal 
or simulated hypoxic conditions were similar, suggesting that these differences were not due 
to energy levels. Proliferation differences between M1 and M2 cells in xenograft tumor 
models also reflected in vitro differences: larger tumors developed with a shorter latency 
from M2 cells compared to M1 cells. Most importantly, tumors arising from M1 xenografts 
all re-expressed endogenous PKM2, and tumors that arose from an M1/M2 mixed xenograft 
originated only from M2 cells. These observations strongly suggested that expression of 
PKM2 during tumorigenesis confers a proliferative advantage to cancer cells.
 
1.19 Inhibition of PKM2 kinase activity is important for the Warburg effect 
How does PKM2 confer this advantage? The authors found that only the PKM2 
isoform bound phosphotyrosine residues. This catalyzed the release of its activator fructose 
bisphosphate (FBP) from its allosteric site, effectively inhibiting its enzymatic activity in 
vitro. This effect could be mimicked in cells by stimulating a growth factor receptor tyrosine 
kinase (RTK) signaling pathway or overexpressing a constitutively active tyrosine kinase. 
Although cells expressing either M2 or a phosphotyrosine binding mutant (M2KE) exhibited 
comparable glycolytic rates, M2 cells grew faster, implying that the inhibition of PKM2 by 
RTK signaling was necessary for this to occur.  Finally, the authors  hypothesized that 
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inhibition of PKM2 led to an accumulation of upstream glycolytic intermediates that could 
serve as substrates in anabolic processes, and validated this by demonstrating through 
radioisotope labeling, that M2 but not M2KE cells, exhibited a higher, and  phosphotyrosine 
peptide-dependent rate of lipid synthesis (Christofk et al., 2008b).                 
In addition, PKM2 has been observed to exist mostly in an inactive dimerized form in 
tumor cells, as opposed to a more active tetrameric configuration in normal cells, further 
enhancing anabolic metabolism (Mazurek et al., 2005). Growth-signalling mediated 
phosphorylation (Hitosugi et al., 2009), and acetylation (Lv et al., 2011) of PKM2 also 
inhibit its kinase activity, facilitating tumor cell proliferation and growth. PKM2 has also 
been demonstrated to be induced by the mammalian target of rapamycin (mTOR) complex, 
an important regulator of cell growth and proliferation, through transcriptional activation by 
the hypoxia-inducible factor 1α (HIF-1α), a known mTOR downstream target (Sun et al., 
2011). PKM2 also functions in a positive-feedback loop with HIF-1α by acting as a 
coactivator of HIF-1, thereby reinforcing its overexpression in tumor cells (Luo et al., 2011; 
Luo and Semenza, 2011).  
The above observations implicate the Warburg effect in cellular anabolism, linking it 
directly to the growth of transformed cells, and provide a mechanistic link between growth 
factor signaling, cellular anabolism and aerobic glycolysis, highlighting the importance of the 
Warburg effect as a cooperative event in tumorigenesis.
1.20 Alternative splicing of the PKM gene 
Although the importance of PKM2 has been repeatedly demonstrated, the mechanism 
of the mutually exclusive (ME) mode of PK-M alternative splicing, which favors the 
apparent inclusion of exon 10 over exon 9 in tumors and exon 9 over exon 10 in normal 
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tissues, remains poorly understood.  Understanding the splicing regulation of the PK-M gene 
is as crucial, if not more so, than understanding its transcriptional regulation, because the 
process of tumorigenesis not only requires an increase in the amount of PK-M transcripts, but 
also a change in the type of transcript that is produced from the mutually exclusive splicing 
of PK-M. 
1.21 Preliminary analyses of the PK-M gene 
An earlier study based on a rat minigene system (Takenaka et al., 1996) concluded 
that 1) the 5’ splice sites of both exons were weak; and 2) conserved elements in intron 8 did 
not affect M2/M1 splicing. Although the first conclusion failed to address why exon 10 is 
preferentially included in cultured cells, the data suggested the presence of splicing 
enhancer/suppressor elements present within both exons and intron 9. In addition, since both 
conclusions were based on crude deletion and exon swapping experiments, a major caveat is 
that the altering of the original context in these constructs could potentially mask regulatory 
elements otherwise present in the wild-type context, or create new regulatory elements that 
are irrelevant, confounding the intepretation of the results.
1.22 PK-M Exon 9 repression in tumor cells  
Recently, we and others demonstrated that the exon-10-included M2 isoform is the 
default choice in cancer and proliferating cells, and also implicated two pairs of splicing-
repressor paralogs—PTB/nPTB and hnRNPA1/A2—in repression of exon 9 (Clower et al., 
2010; David et al., 2010). In addition, hnRNPA1/A2 and PTB have been reported to bind at 
the exon 9 5’ss and in intron 8 near the exon 9 splice sites (David et al., 2010) respectively. 
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However, because the conclusions were derived from in vitro UV-crosslinking experiments, 
it is unclear whether these sites are bona fide ESSs in the context of intact pre-mRNAs in 
vivo, because it is not known how well hnRNPA1 binding to a motif that is part of a 5’ss can 
compete with binding of spliceosomal components, such as U1 and U6 snRNPs. 
 
1.23 Critical cis-elements and the question of Exon 10 definition 
In addition, these experiments did not precisely map the elements involved in M2/M1 
splicing in vivo, making functional follow-up experiments to unearth cognate trans-acting 
factors and the mechanism(s) of action (MOA) difficult. In particular, the crucial question of 
where the critical cis-elements responsible for the characteristic PK-M2 splicing pattern in 
proliferating cells are distributed, i.e., are these elements present in the exons, the introns, or 
both, remained unanswered. It also remained unclear how exon 10 is the “default” exon in 
proliferating cells, i.e., is selection of exon 10 actively promoted, or is exon 10 included 
simply as a consequence of repression of exon 9? 
 
1.24 Splicing Antisense Oligonucleotides 
A method to screen for functional splicing elements, as well as to manipulate splicing 
outcomes in endogenous pre-mRNA involves the use of antisense oligonucleotides (ASO). 
These short oligonucleotides were initially used to downregulate mRNA expression by 
homing to target mRNAs via Watson-Crick base pairing and inducing nuclease mediated-
degradation of nucleotide:RNA hybrids (Crooke, 2001). Their therapeutic potential was first 
demonstrated by Zamecnik and Stephenson, who used ASO to target viral replication in cell 
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culture. More recently, chemical modification has led to a class of nuclease-resistant ASOs 
that have high affinity for their RNA targets. A wide range of backbone-modified ASOs with 
differing chemical properties engineered for different applications include 2′-O-methyl 
phosphorothioate (2OMe) RNA, 2-O-methoxyethyl (MOE) RNA, peptide nucleic acid 
(PNA), locked nucleic acid (LNA) and phosphorodiamidate morpholino (PMO) variants. 
These ASOs work by direct sequence-specific annealing to target mRNA to either block 
splicing cis-elements, or block ribosome recruitment to inhibit translation (Muntoni and 
Wood, 2011; Opalinska and Gewirtz, 2002).  
Splicing ASOs have been used to manipulate and correct aberrantly spliced 
transcripts implicated in disease. They work in two ways: (1) restore  the splicing of an 
aberrantly spliced transcript; and 2) manipulate the splicing of a transcript from one isoform 
to another.
1.25 ASO-mediated splicing correction in disease 
The Kole lab first used ASOs to block cryptic intronic splice sites in the β-globin 
gene that were activated due to mutations that occur in some β-thalassemia patients, 
essentially restoring the normal splicing of the β-globin transcript (Sazani and Kole, 2003).  
Since then, ASOs have been used in the context of other genetic diseases in which a mutation 
of a single gene alters its splicing. In the example of Duchenne muscular dystrophy (DMD),  
missense mutations and deletions in the dystrophin gene (DMD) cause the generation of 
premature termination codons and frameshifted transcripts, specifically in the central portion 
of the gene that encodes a large rod domain made up of 24 large spectrin-like repeats and 
four flexible hinge regions (Hammond and Wood, 2011). Mutations can be compensated by 
removing the mutated or neighboring exons through the use of splicing ASO to produce a 
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shorter mature mRNA transcript and restoring the translational reading frame. The internally 
deleted protein retains many of its crucial functions, enabling it to reduce disease severity 
when used in mouse models of DMD (Alter et al., 2006; Lu et al., 2003; Lu et al., 2005).  
In the example of spinal muscular atrophy (SMA), the therapeutic use of ASOs 
involves restoring the inclusion of the constitutively skipped exon 7 of the SMN2 gene. The 
SMN1 gene is mutated in SMA, giving rise to atrophy of proximal muscles and the 
subsequent degeneration of motor neurons in patients. SMN2 is a paralog of SMN1 and 
differs from SMN1 only by a nucleotide transition in the sequence of exon 7. This A to T 
sequence change induces the skipping of exon 7, producing a truncated and unstable SMN 
protein. ASOs were used to induce the inclusion of SMN2 by targeting splicing silencers 
found in or in the vicinity of exon 7, increasing the expression of the SMN protein. ASOs 
have been used in vivo and have been found to rescue phenotypes in SMA mouse models 
(Hua et al., 2010; Hua et al., 2011; Passini et al., 2011). 
Splicing ASOs have also been used against targets that are important in cancer. The 
most notable example involves the use of ASOs to target the BCL-X gene (Sazani and Kole, 
2003). The Bcl-X gene codes for two splice isoforms with antagonistic functions, through the 
use of two alternative 5’ss. The longer isoform, Bcl-xL has an anti-apoptotic function, while 
the shorter isoform, Bcl-xS, is pro-apoptotic. In cancer cells, the splicing of the Bcl-x gene 
has been demonstrated to be skewed towards the anti-apoptotic Bcl-xL isoform as it 
facilitates cellular survival. ASOs that target enhancer elements near the xL (proximal) 5’ss 
in order to restore the splicing of the xS isoform have been demonstrated to sensitize cells to 
chemotherapeutic agents (Taylor et al., 1999) or to induce apoptosis in cancer cells 
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(Mercatante et al., 2001). Further work is needed to demonstrate the efficacy of these ASOs 
in the in vivo context.
 
1.26 Application of splicing ASO technology to PKM2 splicing in cancer cells 
The successful use of a splicing ASO to switch PKM2 transcripts into PKM1 
transcripts in cancer cells would potentially represent a major therapeutic advance in 
targeting the Warburg effect in solid tumors; it would also be useful in uncovering the 
mechanism by which PKM2 confers a proliferative advantage to cancer cells, through the 
analysis of cellular phenotypes as a result of ASO-mediated loss of PKM2 protein.  
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2.1 Manuscript and Contributions 
 
This manuscript was published in the Journal of Molecular Cell Biology in November 2011. 
Z.W and A.R.K conceived and designed the experiments. Z.W, H.Y.J and D.C performed the 
experiments. M.A performed bioinformatics analysis. Z.W, A.R.K wrote the manuscript.  
2.2 Abstract 
 
Alternative splicing of the pyruvate kinase M gene to generate the M2 isoform promotes 
aerobic glycolysis and tumor growth. However, the cancer-specific alternative splicing 
regulation of PK-M is not completely understood. Here, we demonstrate that PK-M is 
regulated by reciprocal effects on the mutually exclusive exons 9 and 10, such that exon 9 is 
repressed and exon 10 is activated in cancer cells. Strikingly, exonic, rather than intronic, cis-
elements are key determinants of PK-M splicing isoform ratios. Using a systematic sub-
exonic duplication approach, we identify a potent exonic splicing enhancer in exon 10, which 
differs from its homologous counterpart in exon 9 by only two nucleotides. We identify 
SRSF3 as one of the cognate factors, and show that this SR protein activates exon 10 and 
mediates changes in glucose metabolism. These findings provide mechanistic insights into 
the complex regulation of alternative splicing of a key regulator of the Warburg effect, and 
also have implications for other genes with a similar pattern of alternative splicing. 
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2.3 Introduction 
 
Cancer cells exhibit a metabolic phenotype termed aerobic glycolysis, or the Warburg effect, 
characterized by increased glycolysis with lactate generation, regardless of oxygen 
availability (Vander Heiden et al., 2009). Expression of the type II isoform of the pyruvate-
kinase-M gene (PKM2, referred to here as PK-M) mediates this metabolic phenotype, and 
confers a proliferative advantage to tumor cells in vivo (Christofk et al., 2008a). 
 
Pyruvate kinase (PK) catalyzes the final step in glycolysis, generating pyruvate and ATP 
from phosphoenolpyruvate and ADP (Dombrauckas et al., 2005). The PK-M gene consists of 
12 exons; exons 9 and 10 are alternatively spliced in a mutually exclusive fashion to give rise 
to M1 and M2 isoforms, respectively (Noguchi et al., 1986). Exons 9 and 10 each encode a 
56-amino-acid segment that confers distinctive properties to the PK-M isozymes. PK-M1 is 
constitutively active, whereas PK-M2 is allosterically regulated by fructose-1,6-bisphosphate 
(FBP) levels and interaction with tyrosine-phosphorylated signaling proteins (Christofk et al., 
2008b). 
 
 The growth-signal-mediated inhibition of PK-M2 activity is thought to contribute to cancer-
cell growth by decreasing carbon flux through the catabolic glycolytic pathway, allowing 
accumulated upstream intermediates to be shunted to anabolic pathways and thereby 
facilitating cell proliferation (Hitosugi et al., 2009). Consistent with this hypothesis, PK-M2 
is expressed in a broad range of cancer cells, as well as in fetal and undifferentiated adult 
tissues, whereas PK-M1 is expressed predominantly in terminally differentiated tissues 
 29 
(Clower et al., 2010). Despite increasing evidence demonstrating the significance of PK-M2 
isoform expression in cancer-cell metabolism and tumorigenesis, the mechanisms governing 
alternative splicing of the PK-M pre-mRNA are not well understood.  
 
Alternative splicing via a pair of mutually exclusive (ME) exons accounts for  2% of 
alternative splicing in human genes (Chacko and Ranganathan, 2009). ME exons often show 
sequence homology—as is the case for PK-M exons 9 and 10—indicating an exon-
duplication origin (Letunic et al., 2002). Although several mechanisms involved in the 
selection of ME exons in mammalian genes have been described, how these pairs of exons 
are coordinately regulated in a ME fashion is not well understood (Smith, 2005). The 
mechanism underlying the ME splicing pattern of PK-M appears to be novel: for example, 
the length (401 bp) and sequence of intron 9 rules out steric interference effects that could 
prevent double splicing due to the spacing of the branch site and the 5’ splice site (5’ss) 
(Smith and Nadal-Ginard, 1989). 
 
We have begun to dissect the molecular mechanisms underlying PK-M2 alternative splicing 
regulation. Recently, we and others demonstrated that the exon-10-included M2 isoform is 
the default choice in cancer and proliferating cells, and also implicated two pairs of splicing-
repressor paralogs—PTB/nPTB and hnRNPA1/A2—in repression of exon 9 (Clower et al., 
2010; David et al., 2010). However, it remains unclear whether there are additional 
repressors that also block the use of exon 9, and whether exon 10 is the “default” exon in 
proliferating cells, i.e., is selection of exon 10 actively promoted, or is exon 10 included 
simply as a consequence of repression of exon 9? In addition, though hnRNPA1/A2 and PTB 
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have been reported to bind in the intronic regions near the exon 9 splice sites (David et al., 
2010), it remains unclear where the critical cis-elements responsible for the characteristic 
PK-M2 splicing pattern in proliferating cells are distributed, i.e., are these elements present 
in the exons, the introns, or both? 
 
To address these questions, we constructed a PK-M minigene that recapitulates the splicing-
regulatory features of the endogenous gene. Using this minigene and derivatives thereof, we 
demonstrate that exon 10 is activated in cancer cells independently of exon 9 repression. By 
duplicating or swapping exons 9 or 10, we further show that exonic, but not intronic cis-
elements, are the key determinants of PK-M alternative splicing. Using a novel sub-exonic 
duplication strategy, we then mapped an exonic splicing enhancer (ESE) in exon 10, and 
found that SRSF3 (formerly SRp20), an oncogenic member of the serine/arginine-rich (SR) 
protein family of splicing activators, is its cognate binding factor. Knockdown of SRSF3 in 
cancer cells leads to the rescue of PK-M1 expression and a decrease in lactate production and 
cellular proliferation.
2.4 Results   
2.4.1 A PK-M minigene recapitulates alternative splicing of the endogenous gene 
 
The ME exons 9 and 10 of PK-M are identical in length, and highly homologous at both the 
nucleotide and amino-acid sequence levels (Fig. 1A). One crucial difference is that only exon 
10 codes for a key lysine residue within the FBP-binding pocket, and this lysine mediates 
binding to tyrosine-phosphorylated proteins to release FBP and inhibit enzymatic activity 
(Fig. 1A;  
  
To analyze the mechanism of ME splicing of PK-M pre-mRNA, and facilitate the discovery 
of splicing cis-elements, we generated a minigene transcribed from a CMV promoter (Fig. 
1B). The minigene consists of the genomic region encompassing the ME exons 9 and 10, 
introns 8, 9 and 10, and proximal portions of the flanking exons 8 and 11. Detection and 
analysis of minigene-derived transcripts utilized a modified RT-PCR and restriction-
digestion strategy, as described for endogenous PK-M transcripts (Fig. 1B; (Clower et al., 
2010)). To characterize all possible minigene-derived species after transfection into cell 
lines, we selectively amplified them from total cDNA using a forward primer specific for an 
upstream vector sequence, together with a reverse primer annealing to constitutive exon 11 
(Fig. 1B).  
 
Fig. 1C shows the profiles of endogenous and minigene-derived transcripts in HEK-293 cells 
(similar data not shown for HeLa, A172, and SKNBE). The minigene predominantly 
expressed the exon-10-included PK-M2 isoform, paralleling endogenous PK-M2/M1 splicing 
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ratios. Two additional, minor minigene RNAs not found in endogenous PK-M transcripts 
were also reproducibly detected: an RNA lacking both exons 9 and 10, and comprising only 
the flanking exons (Fig. 1C; double-skipped species d) and a variant PK-M2 transcript 
spliced via a cryptic 3’ss upstream of the authentic 3’ss of exon 10 (Fig. 1C and Suppl. Fig. 
1; exon 10 3’ss cryptic species c).  
 
2.4.2 Blocking exon 10 inclusion does not fully rescue exon 9 inclusion  
 
Given the predominant PK-M2 splicing of endogenous and minigene transcripts in 
proliferating cells, we tested whether blocking exon 10 inclusion by inactivating or 
weakening its splice sites might force a corresponding increase in exon 9 inclusion. The 5’ss 
or 3’ss of exon 10 were inactivated by mutating the invariant G residues at the intron borders, 
and the 3’ss was separately weakened by transversions within its upstream polypyrimidine 
tract (PPT) (Fig. 2A).  
 
Mutating the exon 10 5’ss resulted in a larger mRNA with an extended exon 10 (Fig. 2A and 
Suppl. Fig. 1, lanes 5-8; exon 10 5’ss cryptic species e). This mRNA resulted from splicing 
via a cryptic 5’ss 105 nt downstream of the authentic 5’ss of exon 10. There was no 
significant increase in the double-skipped RNA species d. Thus, exon 10 definition was 
essentially preserved, even though the normal 5’ss was inactivated. 
 
In contrast, mutating the exon 10 3’ss largely abrogated exon 10 definition, as seen from the 
large increase in double-skipped transcripts (Fig. 2A and Suppl. Fig. 1, lanes 9-12; species 
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d). A small increase in the exon 10 cryptic 3’ss species c was also observed. These results 
suggest that the exon 10 3’ss is essential for exon 10 definition. Similarly, weakening the 
exon 10 PPT led to some loss of exon 10 definition, as seen from the large increases in 
double-skipped RNA and in the use of the upstream cryptic 3’ss (Fig. 2A, lanes 13-16; 
species c and d). This result implies that exon 10 inclusion is an active process, such that the 
loss of exon 10 activation results in non-productive splicing of the PK-M transcript. 
 
With all three minigene mutants, there was only marginal recovery of exon 9 inclusion (Fig. 
2A, lanes 5-16). In addition, deleting exon 10 from the minigene also led to a similar increase 
in double-skipped mRNA, with the mutant displaying a phenotype identical to that of exon 
10 3’ss inactivation (data not shown). Therefore, exon 9 inclusion in proliferating cells is 
repressed independently of exon 10 splicing. 
2.4.3 Strengthening the splice sites of exon 9 leads to aberrant PK-M splicing  
 
Because blocking exon 10 splicing did not lead to a significant rescue of M1 splicing in 
transformed cells, we tested whether directly strengthening the exon 9 splice sites might do 
so. We therefore mutated the exon 9 5’ss to the consensus 5’ss sequence (Fig. 2B, lanes 5-8), 
and strengthened the exon 9 3’ss by increasing the pyrimidine content of its upstream PPT 
(Fig. 2B, lanes 9-12).  
 
As expected, strengthening either the exon 9 5’ss or 3’ss led to an increase in M1 splicing. 
However, a new exon 9 plus exon 10 doubly-included mRNA species was also observed in 
both cases (Fig, 2B and Suppl. Fig. 1; double-spliced species f). Mutating the 5’ss to the 
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consensus resulted in a large increase in the amount of M1 RNA and in high levels of the 
double-spliced mRNA (Fig. 2B, lanes 5-7), whereas slightly increasing the 3’ss strength gave 
somewhat lower levels of these two mRNAs (lanes 9-11). The concurrent appearance of the 
double-spliced mRNA suggests that exon 10 definition—and by extension, exon 10 
activation—is largely independent of exon 9 splicing. 
 
2.4.4 Exonic splicing silencers and enhancers are key determinants of PK-M splicing 
ratios  
 
To prioritize PK-M regions for cis-element analysis, we next asked whether intronic or 
exonic cis-elements play critical roles in activating exon 10 and/or repressing exon 9. First, 
we duplicated exon 10 in place of exon 9 in the minigene (Fig. 3, lanes 9-12; Suppl. Fig. 1). 
If exon 9 repression depends on cis-elements present in introns 8 or 9, there should be 
inefficient use of the upstream copy of exon 10, because it would be under the influence of 
these repressive elements, and the pattern should be similar to that of the wild-type minigene. 
Instead, we observed the striking appearance of a doubly-included exon 10 mRNA species 
(Fig. 3, lane 9; exon 10 double-included species g) indicating that the upstream exon 10 was 
still activated, regardless of its position. This finding strongly suggests that splicing enhancer 
elements involved in exon 10 definition are present in the exon itself. 
 
Similarly, we duplicated exon 9 in place of exon 10 in the minigene (Fig. 3, lanes 5-8). If 
exon 10 splicing is normally activated through flanking cis-elements in introns 9 or 10, there 
should be a strong increase in exon-9-included transcripts, compared to the wild-type 
minigene, because the downstream copy of exon 9 would now be under the influence of such 
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elements. However, there was no such increase from the exon-9-duplicated minigene 
transcripts (Fig. 3, lanes 5-8). This finding suggests that splicing-silencing elements involved 
in repressing exon 9 are located in the exon itself. 
 
When the positions of exons 9 and 10 were swapped, leaving all the introns unchanged (Fig. 
3, lanes 13-16), the M1 and M2 isoform ratio was similar to that of the wild-type minigene, 
although there was a decrease in M1 abundance, and an expected decrease in the use of the 
cryptic 3’ss upstream of the original exon 10 (i.e., in intron 9), because this 3’ss is now 
juxtaposed with the repressed exon 9 3’ss. This finding indicates that exon 10, when moved 
to exon 9, is spliced as efficiently as in its original location. This striking result suggests that 
exonic cis-elements involved in PK-M splicing are sufficient to activate exon 10 and repress 
exon 9, in a manner that is independent of their respective positions along the gene and the 
influence of their flanking introns. 
 
To confirm the above results, and to determine the role of the splice sites in ME exon use, we 
swapped the 3’ss or 5’ss of both exons. Computational analysis of these splice sites (Yeo and 
Burge, 2004) suggested that the 3’ss of exon 9 is weaker than those of exons 10 and 11 
(Suppl. Fig. 2). Exon 9 inclusion was therefore expected to increase when its 3’ss was 
replaced by the stronger one from exon 10. Instead, we observed a decrease in M1 isoform 
abundance, suggesting that proper definition of exon 9 requires its native, albeit weaker, 3’ss, 
for contextual reasons (Suppl. Fig. 2, lanes 3 and 11). There were no significant changes 
when the 5’ss were swapped (lanes 3 and 7). These observations again indicate that exonic, 
rather intronic, cis-elements are the key determinants of PK-M splicing ratios. 
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2.4.5 A strong ESE in exon 10 is necessary and sufficient for activation of the exon  
 
To test the hypothesis that there are critical ESEs in exon 10, we systematically searched for 
such elements. Taking advantage of the high nucleotide-sequence identity between exons 9 
and 10, and their identical lengths (Fig 1A), we duplicated 15-30 nt stretches of exon 10 into 
the corresponding location in exon 9, in order to find sub-exonic regions that are sufficient to 
activate exon 9 inclusion (Fig. 4A).  
 
We found that the last 30 nt, but not the last 15 nt of exon 10 strongly increased exon 9 
inclusion, suggesting that a strong ESE is present within, or overlaps with, the penultimate 15 
nt of exon 10 (Fig. 4B, compare lanes 4-6 with lanes 7-9). We then analyzed the entire 30-nt 
stretch using SFmap (Akerman et al., 2009; Paz et al., 2010), a method to predict splicing-
regulatory motifs based on their inter-species conservation and sequence environment. This 
analysis yielded a near-consensus, conserved SRSF3 motif (Schaal and Maniatis, 1999) 
within the penultimate 15-nt segment (Suppl. Fig. 3). To determine whether this SRSF3 
motif alone can account for the observed M1 splicing activation, we duplicated the 7-nt 
SRSF3 motif from exon 10 into exon 9, by mutating the only two nucleotides that differ 
between exons 9 and 10 within this heptamer. Remarkably, duplicating only the SRSF3 
motif, but not the flanking 8-nt or the final 15-nt region, activated exon 9 to a similar extent 
as that achieved by duplicating the entire 30-nt region (Fig. 4B, compare lanes 10-12 with 
lanes 7-9 and 13-15). This result strongly suggests that the SRSF3 motif is an actual exon 10 
ESE.  
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We then reciprocally abrogated the motif in exon 10 by mutating it into the corresponding 
exon-9 sequence (Fig. 4C). This resulted in a decrease in exon 10 splicing, as inferred by the 
large increase in double-skipped RNA (Fig. 4D, lanes 10-12; species d), together with the 
concomitant increase in M1 isoform abundance (Fig. 4D, lanes 10-12; species a). Taken 
together, these data suggest that the SRSF3 motif is a bona fide ESE that is both necessary 
and sufficient for exon 10 activation. 
 
2.4.6 SRSF3 binds specifically to the exon-10 ESE 
 
Because the mapped ESE resembles a consensus SRSF3 motif, we used RNA-affinity 
pulldowns to ask whether SRSF3 indeed binds to this RNA sequence. Synthetic 24-nt RNAs 
were covalently linked via their 3’ends to agarose beads, incubated with HeLa nuclear extract 
under splicing conditions, and then washed at two different salt concentrations. Bound 
proteins were then eluted and analyzed specifically for SRSF3 binding by Western blotting 
(Fig. 5). We initially compared RNA sequences 6 to 29 nt upstream from the last 3’ 
nucleotide in both exons (Fig. 5B). As an additional control, we mutated the exon 10 SRSF3 
motif to the consensus (1-nt A to C mutation, AUCGUCC to CUCGUCC). Coomassie-Blue 
staining and mass spectrometry analysis revealed a different composition of bound proteins 
between exon 9 and exon 10 RNAs (Fig. 5A, compare lanes 2 and 3). We observed similar 
patterns of bound proteins under more stringent washing conditions (300 mM instead of 150 
mM KCl; data not shown). More importantly, SRSF3 bound strongly to the exon 10 RNA. 
Because hnRNPA1 bound to all RNAs tested—presumably non-specifically—we used 
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hnRNPA1 as an internal loading control for subsequent analyses. Immunoblotting 
unambiguously revealed that SRSF3 bound only to the exon 10 and consensus SRSF3 RNAs, 
but not to the exon 9 RNA, at both salt concentrations (Fig. 5B).  
 
To pinpoint the precise location of SRSF3 binding in exon 10, we mutated the SRSF3 motif 
to the corresponding exon 9 sequence (Fig. 5C). This resulted in a large decrease in SRSF3 
binding (Fig. 5C), indicating that the motif is necessary for strong SRSF3 binding to these 
short exon 10 RNA fragments. 
  
2.4.7 SRSF3 is necessary for exon 10 inclusion 
 
Although abrogating the SRSF3 motif in exon 10 led to greater exon 9 inclusion (Fig. 4D), 
we could not rule out the presence of functional cis-elements in the corresponding exon 9 
sequence that might influence the observed PK-M1 inclusion ratio. To better assess the effect 
of SRSF3 on exon 10 inclusion, we tested whether knocking down SRSF3 in the context of 
both the wild-type minigene and the duplicated SRSF3 motif minigene mutant (10 SR 
minigene, Fig. 4B) would enhance exon 9 inclusion, as exon 10 inclusion would be expected 
to decrease. Indeed, knocking down SRSF3 using two different siRNAs (Fig. 5D) led to an 
increase in M1 inclusion and in the abundance of the double-skipped RNA for the wild-type 
minigene (Fig. 5E, lanes 1-6), similar to what we observed when we mutated the SRSF3 ESE 
(9 SR minigene, Fig. 4D). We also observed a strong decrease in exon 10 inclusion, and a 
corresponding increase in exon 9 inclusion with the 10 SR minigene (Fig. 5E, lanes 7-12). 
These data indicate that SRSF3 is necessary for exon 10 inclusion. 
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2.4.8 SRSF3 affects endogenous PK-M splicing 
 
We next tested whether SRSF3 could affect endogenous PK-M alternative splicing; we used 
knockdown and overexpression, which, as expected, gave reciprocal effects. Knocking down 
SRSF3 in HEK-293 cells led to a 12-fold increase in PK-M1 mRNA, which was also reflected 
at the protein level (Fig. 6A,B). A previous study found that knocking down SRSF3 led to a 
smaller increase in PK-M1, which was deemed not significant (David et al., 2010), but this 
could have been due to weaker knockdown and/or negative selection resulting from the use of 
a stably transfected shRNA. Interestingly, knocking down SRSF3 additionally resulted in 
some double skipping of both exons 9 and 10 (Fig. 6A)—supporting the notion that SRSF3 
promotes the definition of exon 10. As a reciprocal experiment, we overexpressed SRSF3 in 
the glioblastoma cell line A172 (Supp. Fig. 4B), which expresses relatively high levels of PK-
M1 (Clower et al., 2010) and has low levels of endogenous SRSF3 protein (Suppl. Fig. 4D). 
As expected, overexpression of SRSF3 promoted an increase in M2 levels, and therefore led 
to a 5-fold decrease in M1 levels (Fig. 6C).  
 
2.4.9 SRSF3 activates endogenous PK-M exon 10   
 
To determine whether the above effect of SRSF3 overexpression (Fig. 6C) is due to 
increased activation of exon 10 and/or repression of exon 9, we first rescued M1 inclusion by 
knocking down hnRNPA1/A2 and PTB in HEK-293 cells, and then we overexpressed 
SRSF3 and assessed its effects on endogenous PK-M transcripts (Fig. 6D and Suppl. Fig. 
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4A). SRSF3 overexpression partially restored the level of PK-M2 mRNA (Fig. 6D). This 
observation suggests that SRSF3 only activates PK-M exon 10. Indeed, overexpression of 
SRSF3 did not elicit a change in splicing of the duplicated-exon-9 minigene, and knockdown 
of SRSF3 in the context of the 9 SR minigene had no significant effect on PK-M1/M2 
splicing ratios, further suggesting that SRSF3 does not directly affect exon 9 splicing (Suppl. 
Fig. 5).  
 
2.4.10 SRSF3 is necessary for aerobic glycolysis and cellular proliferation 
 
PK-M isoform ratios influence aerobic glycolysis (Christofk et al., 2008a) , and therefore, we 
determined the effect of SRSF3 knockdown on this process, as assayed by the extent of 
cellular lactate production. SRSF3 knockdown in HEK-293 cells resulted in a significant 2-
fold decrease in lactate production (Fig 6E). Because the Warburg effect also strongly 
influences the rate of cellular proliferation (Christofk et al., 2008a), we next assayed the 
effect of SRSF3 knockdown on cell growth and viability. A 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was performed over the course of 7 days in HEK-
293 cells. Strikingly, SRSF3 knockdown significantly decreased the cellular proliferation 
rate. We conclude that SRSF3 promotes cellular proliferation and aerobic glycolysis at least 
in part by influencing PK-M isoform ratios. Moreover, because the effect of SRSF3 
knockdown was primarily to increase PK-M1 at the protein level (Fig. 6B), this suggests that 
the increase in PK-M1, rather than a decrease in PK-M2, is responsible for the effects on 
metabolism and proliferation.  
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2.5 Discussion 
 
We have demonstrated that PK-M ME splicing involves a two-component circuit: exon 9 is 
repressed and exon 10 is activated in proliferating cells, and these two effects are essentially 
independent of each other (Fig. 7).  
 
By duplicating and swapping ME exons in a PK-M minigene, we showed that the most 
important cis-elements controlling PK-M alternative splicing are located within the ME 
exons themselves. This is the first demonstration of exon-centric alternative splicing 
regulation via ME exons. As a first proof of this principle, we mapped a bona fide SRSF3 
ESE in exon 10 that proved sufficient to activate exon 9 splicing in cancer cells when placed 
in this exon. Although double inclusion of exon 10 was not the major product from the exon-
10-duplication minigene (Fig. 3), this cannot be due to repression via the flanking intron 8 
and 9 regions, because exon 10 was spliced efficiently when it was cleanly swapped with 
exon 9. Instead, we speculate that intronic elements are likely involved in the ME exon 
selection properties of PK-M. 
 
Remarkably, the SRSF3 ESE motif in exon 10 differs from the corresponding exon 9 
sequence by only two nucleotides (Suppl. Fig. 3B). Both nucleotides correspond to wobble 
bases in the corresponding codons (Suppl. Fig. 3A). The first wobble base is highly 
conserved, which might reflect the importance of this nucleotide in mediating SRSF3 
recruitment and functionality. The corresponding two nucleotides in exon 9 are also 
conserved, suggesting strong selection against the creation of an exon 9 SRSF3 activation 
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motif (Suppl. Fig. 3B), However, because we used exon 9 sequences to replace exon 10 
when abrogating the exon 10 SRSF3 ESE, we cannot rule out the existence of a 
corresponding exonic splicing silencing (ESS) element in exon 9. The co-evolution of 
splicing signals in both exons exemplifies the requirement for these exons to be coordinately 
regulated in order to maintain the ME properties of the system. Additionally, the use of two 
wobble nucleotides to code for a key splicing signal illustrates the impact of sequence 
changes that are expected to be translationally neutral, but that nevertheless drastically affect 
the structure of the resulting protein by changing alternative splicing of the entire exon 
(reviewed in (Cartegni et al., 2002)).   
 
Although mutating just two wobble nucleotides in exon 10 to the corresponding exon 9 
sequence (9 SR minigene) gave rise to more double-skipped and PK-M1 mRNAs, this was 
not the case when the surrounding exon 9 sequence was also duplicated (9 1530 and 9 30 
minigenes). This probably reflects the presence of as yet uncharacterized cis-elements in 
exon 9, such as putative ESEs that may compensate for the loss of exon definition upon 
mutation of the SRSF3 motif. 
 
Whereas the 5’ss of exons 9 and 10 do not play a dominant role in exon selection in this 
system—considering that the levels of M1 and M2 mRNAs do not change upon swapping the 
5’ss of the ME exons (Suppl. Fig. 2B)—mutational analysis indicates that the 3’ss are 
necessary for definition of their respective exons, and they compete with each other. It 
appears that exon definition, and ultimately, proper ME exon selection in the PK-M gene, are 
dependent on the outcome of competition between the alternative 3’ ss. We speculate that the 
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recovery of endogenous PK-M1 transcripts upon SRSF3 knockdown may be due to this 
competition mechanism, resulting in a loss of exon 10 definition, and allowing the basal 
splicing machinery to be recruited to the exon 9 3’ss. Loss of exon 10 definition is also 
supported by the increase in the abundance of double-skipped minigene transcripts from the 
wild-type minigene upon SRSF3 knockdown. However, it is unclear why the extent of PK-
M1 inclusion is weaker in minigene transcripts than in endogenous transcripts, leading to the 
accumulation of unproductively spliced double-skipped transcripts.  
 
We were surprised to find no rescue of exon 9 inclusion when its 5’ss was swapped with that 
of exon 10—even though it has been reported that hnRNPA1 represses exon 9 inclusion by 
binding to the exon 9 5’ss (David et al., 2010)—as this swap presumably removed the 
repressive hnRNPA1 binding site; perhaps this lack of rescue reflects contextual effects. 
However, our results confirm and extend the data from an earlier study that duplicated the 
exon 10 5’ss in a heterologous minigene reporter system, and found no change in PK-M 
splicing (Takenaka et al., 1996). Moreover, in the context of intact pre-mRNAs, it is not 
known how well hnRNPA1 binding to a motif that is part of a 5’ss can compete with binding 
of spliceosomal components, such as U1 and U6 snRNPs. Given that hnRNPA1 does have 
strong effects on exon 9 inclusion in vivo (Clower et al., 2010; David et al., 2010), 
hnRNPA1-induced exon 9 repression could occur either indirectly—through hnRNPA1-
mediated regulation of a splicing factor that in turn regulates PK-M alternative splicing—or 
through additional cis-elements located elsewhere on the PK-M pre-mRNA.  
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The change in endogenous levels of PK-M1 when SRSF3 was knocked down was roughly 
comparable to the effects of knocking down the known repressors of exon 9, hnRNPA1/A2 
and PTB (Clower et al., 2010; David et al., 2010). However, knocking down these factors did 
not completely rescue exon 9 inclusion, and as in other systems, we anticipate the existence 
of several additional activators of exon 10 and/or repressors of exon 9 that contribute to 
maintaining exon 10 definition in proliferating cells. With respect to the enhancer region we 
identified in exon 10, knockdown of other candidate splicing factors identified by RNA-
affinity chromatography, namely hnRNPK, and RBM3, did not change PK-M splicing ratios 
(data not shown). 
 
We have demonstrated that the SR protein SRSF3 promotes the inclusion of the PK-M2-
specific alternative exon 10 in transformed cells by binding to an ESE near the 3’ end of the 
exon. Consistent with its expected ability to facilitate cellular proliferation by altering 
glycolytic metabolism, SRSF3 is overexpressed in ovarian cancers (He et al., 2004) and 
cervical cancer cell lines, whereas in normal cervical tissue, its expression is restricted to the 
basal proliferating layers (Jia et al., 2009). SRSF3 is also a downstream target of the 
oncogenic β-catenin/TCF-4 pathway in colorectal cancer cells (Goncalves et al., 2008).  
Moreover, overexpression of SRSF3 was recently found to be sufficient for transformation of 
NIH-3T3 immortal mouse fibroblasts (Jia et al., 2010), indicating that similar to its paralog, 
SRSF1 (Karni et al., 2008), SRSF3 is an oncoprotein. Given the multitude of potential 
SRSF3 downstream target genes, we expect that SRSF3-mediated tumorigenesis reflects 
splicing changes in multiple effector genes, including PK-M. 
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Important questions that remain unanswered include: What are the additional factors that 
govern exon 9 and exon 10 usage in tumor cells? Can the PK-M2 isoform be completely 
switched to the PK-M1 isoform by manipulating the levels of splicing factors in tumor cells? 
How is exon 9 selected as the default spliced exon in quiescent cells? Are there tissue-
specific differences in the mechanisms of exon 9 selection in differentiated cells? Answers to 
these questions will contribute to a better understanding of the regulation of PK-M isoform 
expression in the context of tumorigenesis, which could provide the basis to develop 
splicing-targeted cancer therapeutics. 
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2.6 Experimental Procedures 
 
2.6.1 Cells and transfections 
 
HeLa and HEK-293 cells were grown in DMEM, supplemented with 10% (v/v) FBS, 
penicillin and streptomycin, at 37 °C and 5% CO2. 5 µg of minigene plasmid per 10-cm dish, 
or 1 µg per well of a 6-well plate, was transiently transfected using Lipofectamine 2000 
(Invitrogen). Total RNA from transfected cells was harvested after 36 hr.  
 
2.6.2 RNA interference 
 
Two siRNAs targeting human SFRS3 were obtained from Sigma Genosys, and have the 
sense-strand sequences 5’-CGAUCUAGGUCAAAUGAAA-3’ (SR3#1) and 5’-
CGUAGUCGAUCUAGGUCAA-3’ (SR3#2). siRNAs against hnRNPA1, hnRNPA2, and 
PTB were used as described (Cartegni et al., 2006). 106 HEK-293 cells in 6-well plates were 
transfected with 200 pmol of siRNA duplex using Lipofectamine 2000 (Invitrogen). Cells 
were harvested 48 hr later.  
 
2.6.3 Immunoblotting 
 
Cells were lysed in SDS, and total protein concentration was measured by the Bradford 
assay. 30 µg of total protein was separated by SDS-PAGE and transferred onto 
nitrocellulose, followed by blocking with 5% (w/v) milk in Tris-buffered saline with Tween-
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20, probing with the indicated antibodies, and visualization by enhanced chemiluminescence 
(Roche). Primary antibodies were: β-tubulin (Genscript rAb, 1:5000); hnRNPA1 (mAb UP1-
55, culture supernatant (Hua et al., 2008)); SRSF3 (Zymed mAb, 1:1000); PK-M2 (rabbit, 
1:2000) and PK-M1 (rabbit, 1:2000; (Christofk et al., 2008b)). Secondary antibodies were 
goat anti-mouse or anti-rabbit HRP conjugates, 1:20,000 (Bio-Rad).  
 
2.6.4 Plasmids 
 
DNA oligonucleotides were obtained from Sigma Genosys. The PK-M2 minigene was 
constructed by amplifying a 6.4-kb PK-M exon 8-11 fragment from human genomic DNA 
(Promega) using Phusion High-Fidelity DNA Polymerase (Finnzymes) and primers 
PKMinigeneF (5’-GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3’) and 
PKMinigeneR (5’-GGGGAACTCGAGCTAGACATTCATGGCAAAGTTCACC-3’). The 
product was then digested and cloned between the BamHI and XhoI sites of pcDNA3.1+ 
(Invitrogen). Site-directed mutagenesis using Pfu polymerase (Strategene) was used to 
generate the mutant minigene constructs in Fig. 2. For the constructs in Figs. 3-6, the 
upstream KpnI site 1552 nt downstream of exon 8 was removed by a 1-nt deletion, and an 
EcoRV restriction site was generated 90 nt upstream of exon 9 by a 2-nt insertion to create a 
modified wild-type minigene. See Supplementary experimental procedures for the generation 
of exonic and sub-exonic duplication, exon-swap, and splice-swap constructs. 
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2.6.5 RT-PCR 
 
2-5 µg of total RNA was extracted from cell lines using Trizol (Invitrogen). Contaminating 
DNA was removed with DNAase I (Promega). Reverse transcription was carried out using 
ImPromp-II reverse transcriptase (Promega). Semiquantitative PCR using Amplitaq 
polymerase (Applied Biosystems) was performed by including [α-32P]-dCTP in the reactions. 
The human-specific primer sets used to amplify endogenous transcripts anneal to PK-M 
exons 8 and 11, and their sequences are: hPKMF: 5’-AGAAACAGCCAAAGGGGACT-3’; 
hPKMR: 5’-CATTCATGGCAAAGTTCACC-3’. To amplify minigene-specific transcripts, 
the forward primer was replaced with a primer annealing to the pcDNA3.1(+) vector, 
pcDNAF: 5’-TAATACGACTCACTATAGGG-3’. After 26 amplification cycles for 
minigene-derived transcripts, and 24 cycles for endogenous transcripts, the reactions were 
divided into four aliquots for digestion with NcoI, PstI (New England Biolabs), both, or 
neither. The products were analyzed on a 5% native polyacrylamide gel, visualized by 
autoradiography, and quantified on a FLA-5100 phosphoimager (Fuji Medical Systems) 
using Multi Gauge software Version 2.3. The % M1 mRNA in endogenous transcripts was 
calculated using the GC-content-normalized intensities of the top undigested band (M1, A) 
and the bottom two digested bands (M2, B1 B2) in the PstI-digest lanes. The % M1 mRNA 
from minigene-transcripts was calculated using the GC-content-normalized intensities of the 
top undigested band (a, M1) and other higher-mobility digested bands corresponding to M2 
and its variant species (b – g, as described above) in the PstI-digest lanes. All the PCR 
products were gel-purified, cloned, and sequenced to verify their identities. 
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2.6.6 RNA-affinity chromatography and mass spectrometry 
 
RNA-affinity chromatography was performed as described (Caputi et al., 1999; Hua et al., 
2008). RNA oligonucleotides were obtained from Sigma Genosys. 10 nanomoles of each 
RNA was oxidized with sodium m-periodate in a 24-µl reaction and mixed with 100 µl (1:1 
slurry) of adipic-acid-dihydrazide agarose beads (Sigma) by rotation overnight at 4 °C. A 
250-µl in vitro splicing reaction mix including 100 µl of HeLa nuclear extract was added to 
50 µl RNA-bound beads equilibrated with buffer D (Mayeda and Krainer, 1999) containing 
0.1 M KCl. Mixtures were incubated at 30 °C for 40 min and divided into two aliquots for 
washing three times with buffer D containing either 150 mM or 300 mM KCl. After the final 
wash, the beads were resuspended in 75 µl of 4× Laemmli buffer and boiled for 5 min to 
elute bound proteins. 5 µl of each protein sample was loaded on a 12 % SDS polyacrylamide 
gel for immunoblotting. 15 µl of sample was used for Coomassie-Blue staining. Prominent 
bands were excised for in-gel trypsin digestion. The samples were then processed and 
analyzed by mass spectrometry at the Cold Spring Harbor Proteomics Core.  
 
2.6.7 Lactate assay 
 
For measurements of lactate secretion, cells were transfected with siRNA in 6-well plates. 24 
hr later, the cells were replated (three replicates per condition) at subconfluent density (25,000 
cells/well) in 12-well dishes, and after 24 hr, the cells were switched to serum-free medium 
without phenol red for 20 min, and lactate secreted into the medium over this time was 
measured, in triplicate for each sample, using the colorimetric mode of a Lactate Assay Kit II 
(Biovision Inc.). Optical density readings at 450 nm were averaged for each sample replicate 
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set, then averaged for each condition replicate set, and finally normalized to the cell number 
measured from parallel wells.  
 
2.6.8 MTT assay 
 
3×106 HEK-293 cells were transfected with 400 pmol of luciferase control or SRSF3 siRNA 
in a 6-cm dish. After 24 hr, cells were seeded into 96-well plates (2500 cells/well). The next 
day, and every two days thereafter, MTT (Sigma) was added to fresh medium at a final 
concentration of 0.5 mg/ml. Cells were then incubated at 37 °C for 4 hr and then solubilized 
with DMSO. Optical density at 560 nm was then determined for each well and averaged. 
2.7 Supplementary Experimental Procedures 
Table 2.7-1 Site-directed mutagenesis. 
 
 
Site-directed mutagenesis using Pfu polymerase (Strategene) was used to generate the mutant 
minigene constructs in Figure 2. For the constructs in Figures 3-6, the upstream KpnI site 
1552 nt downstream of exon 8 was removed by a 1-nt deletion, and an EcoRV restriction site 
was generated 90 nt upstream of exon 9 by a 2-nt insertion to create a modified wild-type 
minigene.
Mutant 
Name  
Sequences of Mutagenesis Primer Pairs 
Exon 10 5’ss 
mutant  
F: 5'-AAGTCTGGCAGATAGGAGGCGGCAG-3'   
R: 5'-CTGCCGCCTCCTATCTGCCAGACTT-3' 
 
Exon 10 3’ss 
mutant 
F: 5'-GTTGCTCCCCTAAATTGCCCGTGAGG-3' 
R: 5’-CCTCACGGGCAATTTAGGGGAGCAAC-3' 
 
Exon 10 Py 
Down 
mutant 
F: 5’-CCCTCTGGACGGATGTTGGAGAGATAGATTGCCCGTGAGGCAG-
3’ 
R: 5’-CTGCCTCACGGGCAATCTATCTCTCCAACATCCGTCCAGAGGG-
3’ 
 
Exon 10 5’ss 
consensus 
mutant 
F: 5’-CGGAGTCTGGCAGGTAAGTGCCTAAGGGCAGGTAAC-3’ 
R: 5’-GTTACCTGCCCTTAGGCACTTACCTGCCAGACTCCG-3’ 
 
Exon 10 3’ss 
Py Up 
mutant 
F: 5’-GCCCCCTCTTCCCCTTTTCCTTACAGATAGCTCG-3’ 
R: 5’-CGAGCTATCTGTAAGGAAAAGGGGAAGAGGGGGC-3’ 
EcoRV 
insertational 
minigene 
mutant 
F: 5’-CTTCCTCTCTGATATCAATTCCCCATTCTG-3’ 
R: 5’-AGAATGGGGAATTGATATCAGAGAGGAAG-3’ 
KpnI 
inactivation  
minigene 
mutant 
F: 5’-GAGCCAAGATGGACCAGCCTAGGTG-3’ 
R: 5’-CACCTAGGCTGGTCCATCTTGGCTC-3’ 
Table 2.7-2 Exon duplication and swaps 
 
Fragments A and B were individually generated using the primer pairs indicated in the table, 
with Phusion High-Fidelity polymerase (Finnzymes), and then gel-purified (Qiagen). Both 
fragments were then joined by OE PCR using Pfu polymerase (Stratagene). OE PCR end  
Exon 9 
Duplication 
Sequence of Primer Pairs 
 
Fragment A 
(exon 9 + 
flanking exon 
10) 
 
F: 5’-TGGACGGATGTTGCTCCCCTAATAGCTCGTGAGGCTGAGGC-3’ 
R: 5’- 
GGTACCACTGAGCAGGGCATTCCAGGGAGCCGCTGCCGCCTCCTAC 
CTGCCAGACTCCGTCAGAAC-3’ 
Fragment B  
FEcoRV: 5’-GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3’ 
           R: 5’-CTAGGGGAGCAACATCCGTCCA-3’ 
 
Exon 10 
Duplication 
                                               Sequence of Primer Pairs 
 
Fragment A 
(exon 10 + 
flanking) exon 
9) 
 
F: 5’-
TTCCCCATTCTGTCTTCCCATGTGTTGTGTCTCGTTTTTTTCCTCCTCCTT
CCCTCTTCCTTGCCCCCTCTTCCCCTAAACCTTACAGATTGCCCGTGAGG
CAGAG-3’ 
R: 5’-GTGTTACCTGCCCTTAGGGCCCTACCTGCCAGACTTGGTGAGGAC-
3’ 
 
 
Fragment B 
        
         F: 5’-GTAGGGCCCTAAGGGCAGGTAACAC-3’ 
RKpnI: 5’-GGGGAAGGTACCACTGAGCAGGGCATT-3’ 
 
Exon  Swap Sequence of Primer Pairs 
Fragment A 
(Template: exon 
9 duplication) 
  
            F: 5’-GTAGGGCCCTAAGGGCAGGTAACAC-3’ 
   RKpnI: 5’-GGGGAAGGTACCACTGAGCAGGGCATT-3’ 
 
Fragment B 
(Template: exon 
10 duplication) 
 
FEcoRV: 5’-GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3’ 
           R: 5’-CTAGGGGAGCAACATCCGTCCA-3’ 
 
OE PCR End 
Primers 
FEcoRV: 5’-GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3’ 
   RKpnI: 5’-GGGGAAGGTACCACTGAGCAGGGCATT-3’ 
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primers are indicated in bold in the table. The chimeric fragment (A+B) was then digested 
with KpnI and EcoRV, gel-purified and ligated between the EcoRV and KpnI restriction sites 
in the modified PK-M minigene. For generation of the exon-swap minigenes, the same 
procedure was carried out, except that different templates (indicated in the table) were used 
to generate Fragments A and B. 
Table 2.7-3 Splice site swaps 
Exon 9 5’ss 
duplication 
Sequences of Primer Pairs 
Fragment A FEcoRV 
R: 5’-
GGGGAAGGTACCACTGAGCAGGGCATTCCAGGGAGCCGCTGCCGGGCC 
CTACCTGCCAGACTTGGTGAGGACGATTATGGCC-3’ 
Exon 10 5’ss 
duplication 
 
Fragment A FEcoRV 
R: 5’-TAACAGTGTTACCTGCCCTTAGCCT 
CCTACCTGCCAGACTCCGTCAGAA-3’ 
Fragment B F: 5’-
AGGCTAAGGGCAGGTAACACTGTTAGGATAACCAGCCTCTTGCTCCAC
CT-3’   
RKpnI 
 
5’ss swap Same primer pairs as for exon swap. Template for Fragment A is exon 9 5’ss A+B 
duplication fragment; template for Fragment B is exon 10 5’ss duplication A+B 
fragment.  
Exon 9 3’ss  
duplication 
Sequences of Primer Pairs 
Fragment A FEcoRV 
R:5’-CTCTGCCTCACGGGCAATCTGTAAGGTTTACATCCGTCCAGAGGG 
ACGAGAGGGGGACAGAGCTTT-3’ 
 
Fragment B F: CCCTCTGGACGGATG TAAACCTTACAG ATTGCCCGTGAGGCAGAG-
3’ 
RKpnI 
 
Exon 10 3’ss 
duplication 
F: 5’-
TTCCCCATTCTGTCTTCCCATGTGTTGTGTCTCGTTTTTTTCCTCCTCCTT
CCCTCTTCCTTGCCCCCTCTTCCCC TTGCTCCCCTAG 
ATAGCTCGTGAGGCTGAGGCAG-3’ 
RKpnI 
 
3’ss swap Same primers pairs as for exon swap. Template for Fragment A is exon 9 3’ss 
duplication A+B fragment; template for Fragment B is exon 10 3’ss duplication 
A+B fragment. 
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Construction procedures are identical to II. Templates for 5’ss and 3’ss swap are indicated in 
the above table. 
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Table 2.7-4 Sub exonic duplications 
Name Oligonucleotide sequence 
Exon9Fwd 5’-CCCTAAACCTTACAGATAGCTCGTGAGGCTGAG 
GCAGCCATGTTCCACCGCAAGCTGTTTGAAGAA 
CTTGTGCGAGCCTCAAGTCACTCCACAGACCTC 
ATGGAAGCCAT-3’ 
 
10 15 5’-CCCTTAGGGCCCTACCTGCCAGACTTGGT 
GAGAACTATCAAAGCTGCTGCTAAACACT 
TATAAGAAGCCTCCACGCTGCCCATGGCC 
ATGGCTTCCATGAGGTCTG-3’ 
 
10 30 5’-CCCTTAGGGCCCTACCTGCCAGACTTGGT 
GAGGACGATTATGGCCGCTGCTAAACACT 
TATAAGAAGCCTCCACGCTGCCCATGGCC 
ATGGCTTCCATGAGGTCTG-3’ 
 
10 SR 5’-CCCTTAGGGCCCTACCTGCCAGACTCCGT 
CAGGACGATCAAAGCTGCTGCTAAACACT 
TATAAGAAGCCTCCACGCTGCCCATGGCC 
ATGGCTTCCATGAGGTCTG-3’ 
 
10 5’ 5’-CCCTTAGGGCCCTACCTGCCAGACTCCGT 
CAGAACTATTATGGCTGCTGCTAAACACTT 
ATAAGAAGCCTCCACGCTGCCCATGGCCA 
TGGCTTCCATGAGGTCTG-3’ 
 
Exon10Fwd 5’-ATGTTGCTCCCCTAGATTGCCCGTGAGGC 
AGAGGCTGCCATCTACCACTTGCAATTAT 
TTGAGGAACTCCGCCGCCTGGCGCCCAT 
TACCAGCGACCCCACAGAAGCCAC-3’ 
 
9 30 5’-CGCTGCCGCCTCCTACCTGCCAGACTCC 
GTCAGAACTATCAAAGCTCCACTGCAGCA 
CTTGAAGGAGGCCTCCACGGCACCCACG 
GCGGTGGCTTCTGTGGGGTCGCT-3’ 
 
9 1530 5’-CGCTGCCGCCTCCTACCTGCCAGACTTG 
GTGAGAACTATCAAAGCTCCACTGCAGC 
ACTTGAAGGAGGCCTCCACGGCACCCAC 
GGCGGTGGCTTCTGTGGGGTCGCT-3’ 
 
9 SR 5’-CGCTGCCGCCTCCTACCTGCCAGACTTG 
GTGAGAACTATTATGGCCCCACTGCAGC 
ACTTGAAGGAGGCCTCCACGGCACCCAC 
GGCGGTGGCTTCTGTGGGGTCGCT-3’ 
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For exon 10 sub-exonic duplications, a 110-nt oligonucleotide (Exon9Fwd) that includes the 
5’ sense DNA sequence of exon 9, was annealed with a variable106-nt oligonucleotide that 
includes the 3’ antisense DNA sequence of exon 9, and amplified using the following OE 
PCR primer pairs: Ex10ADupF: 5’-
TTCCCCATTCTGTCTTCCCATGTGTTGTGTCTCGTTTTTTTCCTCCTCCTTCCCTCTT
CCTTGCCCCCTCTTCCCCTAAACCTTACAG-3’ and  Ex10ADupR: 5’-
AGTGTTACCTGCCCTTAGGGCCCTAC-3’. The 106-nt oligonucleotide carries mutations 
that duplicate specific stretches of exon 10 over the corresponding region of exon 9. The 
sequences of these oligonucleotides are shown below. Another fragment was amplified from 
the wild-type minigene using the following primer pairs: Ex10BF: 5’-
GTAGGGCCCTAAGGGCAGGTAACAC-3’ and RKpnI. Both fragments were then subject 
to a second OE PCR reaction using the same procedures and primers as those used for exon 
swaps.  
For exon 9 sub-exonic duplications, a 110-nt oligonucleotide (Exon10Fwd) that includes the 
5’ sense DNA sequence of exon 10, was annealed with a variable 108-nt oligonucleotide that 
includes the 3’ antisense DNA sequence of exon 10, and amplified using the OE PCR primer 
pairs: Ex9ADupF: 5’-TGGACGGATGTTGCTCCCCTAG-3’ and Ex9ADupR: 5’-
GGTACCACTGAGCAGGGCATTCCAGGGAGCCGCTGCCGCCTCCTAC-3’. The 108-
nt oligonucleotide carries mutations that duplicate specific stretches of exon 9 over the 
corresponding region in exon 10. The sequences of these oligonucleotides are shown below. 
Another fragment was amplified from the wild-type minigene using the following primer 
pairs: FEcoRV and Ex9BR: 5’-GTAGGGCCCTAAGGGCAGGTAACAC-3’. Both 
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fragments were then subjected to a second OE PCR reaction using the same procedures and 
primers as those used for exon swaps. 
Oligonucleotide sequences used for exon 9 and 10 sub-exonic duplications. The variable 
106-nt and 108-nt sequences were used in the construction of specified sub-exonic 
duplication mutants and are named after them. 
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2.8 Figures and Figure Legends 
Figure 2.8-1 
 
2.8.1 Figure 1. Detection of endogenous and minigene-specific PK-M spliced isoforms   
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(A) Nucleotide (top) and amino-acid (bottom) sequence alignments of ME exons 9 (M1) and 
10 (M2). Identical nucleotides are shown by vertical dashes. Identical and similar amino 
acids are highlighted in red and yellow, respectively. The key phosphotyrosine-binding 
residue and the fructose-1,6-bisphosphate (FBP)-binding pocket of PK-M2 are indicated. The 
percentages of nucleotide and amino acid identity are shown.  
(B) Diagram of the human PK-M minigene. The minigene comprises the intact introns 8, 9, 
and 10, the intact alternative exons 9 and 10, and portions of the flanking constitutive exons 8 
and 11. The numbers above each exon and intron show the length in nucleotides. A vector-
specific forward primer (dashed arrow) and a reverse primer annealing to exon 11 were used 
to amplify minigene-derived transcripts; to amplify endogenous transcripts in untransfected 
cells, a forward primer annealing to exon 8 (solid arrow) was used instead. To distinguish 
between exon-9-included (M1 isoform) and exon-10-included (M2 isoform) transcripts, 
cDNA amplicons were cleaved with NcoI (N), PstI (P) or both (NP), as described (Clower et 
al., 2010). Note the additional NcoI site at the 5’ end of the PK-M minigene, which is absent 
from the endogenous gene. 
(C) Radioactive RT-PCR and restriction digest of endogenous and minigene-derived PK-M 
transcripts in HEK-293 cells. RNA was isolated from untransfected cells or 48 hr after 
transfection of the plasmid minigene. Bands marked with asterisks (*) indicate restriction 
fragments corresponding to unspliced PK-M pre-mRNA. cDNAs and fragments from 
endogenous mRNAs are indicated on the left in uppercase font; those derived from 
minigene-specific transcripts are shown on the right in lowercase bold font. The most 
important bands are indicated in blue font. The bands correspond to: uncut M1 fragment (A, 
398 nt; a, 481 nt); uncut M2 fragment (B, 398 nt; b, 481 nt); NcoI-cleaved M1 3’ fragment 
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(A1, 248 nt; a1, 248 nt); NcoI-cleaved M1 5’ fragment (A2, 144 nt; a2, 150 nt); PstI-cleaved 
M2 5’ fragment (B2, 185 nt; b2, 268 nt); PstI-cleaved M2 3’ fragment (B1, 213 nt; b3, 213 
nt). Minigene M2 cDNA is cleaved by NcoI, giving rise to b1 (404 nt). Two additional 
species are observed from minigene-specific transcripts: a spliced mRNA that skips both 
exons 9 and 10 (d, 314 nt) and is cleaved by NcoI (d1, 237 nt), and an M2 transcript that uses 
a cryptic 3’ splice site 115 nt upstream of the authentic 3’ss of exon 10 (c, 596 nt), and whose 
3’ fragment after PstI digestion is identical to b3. Due to its low abundance, the 
corresponding 5’ end after PstI digestion can only be detected with certain mutant minigenes 
(see Fig. 2A). The 5’ end of the PstI-cleaved M2 fragment, b2, is additionally cleaved by 
NcoI to a shorter fragment (b4, 194 nt) plus a 74-nt fragment that runs off the gel. See Suppl. 
Fig. 1 for a detailed description of these M2-variant species. The numbers below the gel 
indicate the percentage of exon 9-included transcripts (% M1); standard deviations (s.d.) are 
≤ 0.2% (n≥3). 
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Figure 2.8-2 
 
2.8.2 Figure 2. Effects of splice-site relative strengths on inclusion of exon 9 
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Mutant minigenes were analyzed by transient transfection into HEK-293 cells, followed by 
radioactive RT-PCR and restriction digests, as in Fig. 1C. 
(A) Mutations that inactivate or weaken the splice sites (ss) of exon 10. The mutated 5’ss, 
3’ss, or PPTnucleotides are indicated in light blue. Numbers indicate the position of the 
mutated nucleotide, either upstream (+), or downstream (-) of the exon. Bands marked with 
asterisks (*) are fragments of PK-M pre-mRNA, as in Fig. 1C. Bands already described in 
Fig. 1C are indicated on the left. New and/or important bands are indicated on the right, and 
the key bands are labeled in blue font (see also Suppl. Fig. 1). The 5’ss mutation gives rise to 
a new M2 variant (e, 586 nt) derived from use of a cryptic 5’ss 105 nt downstream of the 
authentic 5’ss; this band is cleaved by NcoI (e1, 509 nt), and PstI digestion generates a longer 
3’ fragment (e2, 318 nt). The increase in the M2 3’ss cryptic variant (c, as described in Fig. 
1C) upon mutation of the PPT or 3’ss allows detection of the 5’ PstI fragment (c3, 383 nt). 
The % M1 inclusion is indicated at the bottom; s.d.: 0.2% (WT); 0.3% (Exon 10 5’ss mut); 
2% (Exon 10 3’ss mut); and 2% (Exon 10 Py↓) (n≥3). 
(B) Mutations that strengthen the splice sites of exon 9. The mutated 5’ss and PPT 
nucleotides are indicated in light blue. Uppercase and lowercase letters indicate exonic and 
intronic sequences, respectively. Bands are labeled as in panel A. A new exon 9 – exon 10 
doubly-included mRNA is indicated on the right (f, 648 nt). This band is sensitive to both 
PstI (f1, 435 nt) and NcoI (f2, 415 nt) digestion. See also Suppl. Fig. 1. The % M1 inclusion 
is indicated at the bottom; s.d.: 0.2% (WT), 4% (Exon 9 5’ss con) and 3% (Exon 9 3’ss Py↑) 
(n≥3).  
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Figure 2.8-3 
 
 
 
2.8.3 Figure 3. Effects of exonic cis-elements on PK-M alternative splicing 
 
Mutant minigenes were analyzed by transient transfection into HEK-293 cells, followed by 
radioactive RT-PCR and restriction digests, as in Fig. 1C. 
Minigenes were constructed with clean duplications or swaps of exons 9 and 10, as shown 
schematically at the top. Bands marked with black asterisks (*) or labeled on the left are as 
described in Fig. 1C. Key bands are labeled in blue font. The band marked with a red asterisk 
indicates a non-reproducible PCR artifact. A new exon 10 – exon 10 doubly-included mRNA 
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expressed from the Exon 10 Dup minigene is indicated on the right (g, 648 nt). It generates 
unique fragments upon NcoI (g1, 571 nt) and PstI (g2, 167 nt) digestion. See also Suppl. Fig. 
1.  
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Figure 2.8-4 
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2.8.4 Figure 4. Mapping an ESE in exon 10 
 
(A) Method used to map an ESE within the last 30 nt of exon 10. The indicated exon 9 
(green) nucleotides were mutated to corresponding exon 10 (red) sequences. The last 30 nt of 
exon 10, when moved to exon 9, activated inclusion of exon 9. An SRSF3 SELEX motif 
(Schaal and Maniatis, 1999) identified by a SFmap (Akerman et al., 2009) is shown by a 
black rectangle. Exon-10 candidate regions that were duplicated into exon 9 are indicated at 
the bottom, and the construct names (red) are given on the left.  
(B) The SRSF3 motif is the ESE in the last 30 nt of exon 10. The constructs from (A) are 
indicated at the top. Labeled bands are as in Fig. 1C. The % M1 inclusion is shown at the 
bottom (n≥3). Duplication of the exon 10 SRSF3 motif into exon 9 was sufficient to rescue 
exon 9 inclusion. The % M1 inclusion is indicated at the bottom; s.d.: 0.2% (WT), 0.1% (10 
15), 5% (10 30), 4% (10 SR), 1% (10 5') (n=3). 
(C) Replacing the SRSF3 motif in exon 10 by duplicating exon 9 sequences. The indicated 
exon 10 (red) nucleotides were mutated to the corresponding exon 9 (green) sequences. Exon 
9 regions that were duplicated into exon 10 are indicated below, and the construct names 
(green) are given on the left.  
(D) Inactivating the SRSF3 motif in exon 10 causes skipping of exon 10. Candidate exon 9 
regions duplicated into exon 10 are indicated at the top. Labeled bands are as in Fig. 1C. % 
M1-included and % double-skipped (% Skp) transcripts are indicated below. Inactivating the 
SRSF3 motif in exon 10 is sufficient to increase the abundance of the double-skipped RNA 
species Transcript-level changes are indicated at the bottom; s.d.: 0.3% (WT), 0.3% (9 30), 
1% (9 15 30), 2% (9 SR) (n=3). 
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Figure 2.8-5 
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2.8.5 Figure 5. SRSF3 binds to the motif in exon 10 and is necessary for exon 10 
inclusion 
(A) The indicated RNAs covalently linked to agarose beads were incubated with HeLa cell 
nuclear extract under splicing conditions, and the beads were washed three times with buffer 
containing 150 mM KCl. Bound proteins were eluted with SDS and analyzed by SDS-PAGE 
and Coomassie-Blue staining. The mobilities of size markers (M) are indicated. Prominent 
bands were excised and analyzed by mass spectrometry; the identified proteins are indicated 
on the right.  
(B) (C) Sequences of synthetic RNA oligonucleotides used for affinity pulldowns, and 
Western-blotting analysis. Descriptive names of RNAs are indicated on the left. The SRSF3 
motif are enclosed by rectangles. Underlined nucleotides indicate the differences between the 
SRSF3 motif and the corresponding sequences in exon 9. Western blots of eluted proteins are 
shown on the right of each set of sequences. The RNAs used and wash conditions are 
indicated at the top. Antibodies against SRSF3 and hnRNPA1 were used. HeLa nuclear 
extract was used as a positive control; hnRNPA1 was used as a loading control, as it binds to 
these short RNAs to similar extents. 
(D) (E) The indicated SRSF3 siRNA or control luciferase siRNA was co-transfected into 
HEK-293 cells with the wild-type or 10 SR minigene. Knockdown of SRSF3 was verified by 
immunoblotting, as shown in (D). Minigene-specific transcript-level changes for PK-M1 and 
PK-M2 are shown in (E). siRNAs used are indicated at the top. Labeled bands are as in Fig. 
1C. Asterisks indicate PstI-cleaved pre-mRNA. % M1-included, % M2-included, and % 
double-skipped (% Skp) transcripts are indicated below, with the following s.d.: 0.3% 
(WT/luc), 1.2% (WT/SR3#1), 1.5% (WT/SR3#2), 5.7% (10SR/luc), 3.5% (10SR/SR3#1), 
 69 
2.7% (10SR/SR3#2) (n=4). P-values (Student’s t-test) comparing % M2 from luc siRNA to 
that from SR3#1 and SR3#2 siRNAs co-transfected with the 10 SR minigene were 0.01 and 
0.02, respectively.  
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Figure 2.8-6 
 
 71 
2.8.6 Figure 6. SRSF3 affects endogenous levels of PK-M1/M2, aerobic glycolysis, and 
cellular proliferation 
 
(A) (B) The indicated SRSF3 siRNA or control luciferase siRNA was transfected into HEK-
293 cells. (A) shows transcript-level changes for PK-M1 and PK-M2. % M1 is indicated at 
the bottom, with the following s.d.: ≤ 0.2% (luc); 0.3 % (SRSF3) (n = 3). (B) shows changes 
at the protein level, as seen in a representative blot. 
(C) T7-tagged SRSF3 cDNA was transfected in increasing amounts into A172 cells. Cells 
were harvested after 48 hr. PK-M mRNA level was determined by RT-PCR. s.d. ≤1% in all 
cases (n=5). 
(D) hnRNPA1/A2/PTB siRNAs were co-transfected into HEK-293 cells, followed by 
transfection of SRSF3 cDNA 24 hr later. Cells were harvested 36 hr after the second 
transfection. Transcript-level changes are indicated at the bottom, with the following s.d.: 1% 
(A1/A2/PTB siRNA); 3% (A1/A2/PTB siRNA + SRSF3) (n=5). p-value (Student’s t-test) 
comparing A1/A2/PTB siRNA with A1/A2/PTB+SRSF3 is 0.002.  
(E) The indicated SRSF3 siRNA or luciferase siRNA was transfected into HEK-293 cells. 
Lactate production was measured 48 hr after transfection. Error bars represent s.d.; n = 3. * 
P<0.05 (Student’s t-test). 
(F) Analysis of cell proliferation by standard MTT Assay. HEK-293 cells were transfected 
with luciferase or SRSF3 siRNA and plated into 96-wells. Error bars represent the standard 
error of the mean. Day 1 is the next day after seeding.  
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Figure 2.8-7 
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2.8.7 Figure 7. Regulation of PK-M splicing in cancer cells 
  
In quiescent or differentiated cells, exon 9 is the default spliced exon. In transformed cells, 
overexpression of oncogenic splicing factors leads to the simultaneous repression of exon 9 
and activation of exon 10. Binding of SRSF3 to the activation motif near the 3’ end of exon 
10 is proposed to enhance exon definition by facilitating spliceosomal recruitment to the 3’ss 
of this exon. Additional, unknown activators (green ovals) likely contribute to exon 10 
recognition. Upregulated splicing repressors (pink ovals) that presumably act through 
silencing motifs in exon 9 and introns 8 and 9, including hnRNPA1/A2 and PTB (Clower et 
al., 2010; David et al., 2010), further reinforce exon 10 selection in transformed cells by 
repressing exon 9 inclusion. When SRSF3 is less abundant (or when we mutated the SRSF3 
activation motif), loss of exon 10 definition occurs, and leads to increased exon 10 skipping. 
The exon 9 3’ss is then able to compete more effectively for spliceosomal components, 
leading to an increase in exon 9 inclusion.  
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Figure 2.8-8 
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2.8.8 Supplementary Figure 1. Diagram of PK-M minigene-specific RNA species in 
Figs. 1-4. 
 
Names of transcript species are indicated in the first column, and their structures are shown 
in the second column. Shorthand band designations used in the figures are indicated on the 
left of each diagram. Boxes filled in white, green, red, and black represent exons 8, 9, 10 and 
11, respectively. Lines linking boxes indicate retained intronic sequences, and numbers with 
arrows below the lines specify their length. Fragments arising from NcoI (third column) or 
PstI (last column) digestion are given a unique designation (e.g., fragment g2 from PstI 
digestion of PCR product from RNA species g) if they are not identical to already-named 
fragments (e.g., fragment b2 also occurs from PstI digestion of PCR product g). Double 
digestion with NcoI and PstI results in cleavage of band b2, as described in the legend to Fig. 
1C. All species were cloned and sequenced to confirm their identities.  
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Figure 2.8-9 
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2.8.9 Supplementary Figure 2. The splice sites of exons 9 and 10 play only a minor 
role in PK-M alternative splicing . 
 
(A) Bioinformatic analysis of PK-M splice-site strengths. Normalized 5’- and 3’-splice-site 
strengths of exons (as indicated by dashed lines) were plotted on the Y-axis using a published 
method (Yeo and Burge, 2004). 
(B) The splicing patterns of PK-M minigene splice-site-swap mutants do not differ much 
from that of the wild-type minigene. 5’ss- and 3’ss-swap mutants are schematically indicated 
at the top. 9 nt comprising the 5’splice site (3 nt of the exon and 6 nt of the intron) and 12 nt 
comprising the 3’splice site (2 nt of the exon and 10 nt of the intron) were swapped, 
respectively. Labeled bands are as in Fig. 1 and Suppl. Fig. 1. The numbers below the panels 
indicate the percentage of exon-9-included (% M1) transcripts (n≥3). 
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Figure 2.8-10 
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2.8.10 Supplementary Figure 3. Codon and conservation analysis of PK-M exons 9 and 
10. 
(A) Two wobble nucleotides define the exon 10 SRSF3 activation motif. Alignment of PK-M 
exon 9 (top) with exon 10 (bottom) DNA sequences. The SRSF3 activation motif is indicated 
by the red rectangle. The sequences were grouped into codons to indicate the reading frame. 
Amino acids coded by the PK-M1 and M2 open reading frames are shown at the top and 
bottom, respectively. The gold rectangle highlights the key phosphotyrosine-binding lysine 
residue that functionally differentiates the PK-M2 from the PK-M1 isozyme. 
(B) Conservation analysis of SRSF3 motif. Alignment of PK-M exon 10 (top) and PK-M 
exon 9 (bottom) RNA sequences from different species. The exon 10 alignment shows the 
SRSF3 motif, indicated with red letters and enclosed by a red box, and partial surrounding 
sequence. The exon 9 alignment shows the region corresponding to the exon 10 SRSF3 
motif, indicated with red letters and enclosed by a green box, and partial surrounding 
sequence. Bold black letters highlight the nucleotide differences between the SRSF3 motif in 
exon 10 and the corresponding region in exon 9. The conservation index of each nucleotide is 
indicated below by the black histogram. 
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Figure 2.8-11 
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2.8.11 Supplementary Figure 4. Western blots for overexpression and knockdown 
experiments in Figure 6. 
 
(A,B) Overexpression of SRSF3 in HEK-293 (A) and A172 (B) cells. Cells were transfected 
with plasmids encoding T7-tagged SRSF3 cDNA (Cáceres et al., 1998) in increasing 
amounts. Cell lysates were prepared after 48 hr, and overexpression was verified by 
immunoblotting with monoclonal antibodies against SRSF3 or the T7 tag, and tubulin as a 
loading control. 
(C) Overexpression of SRSF3 combined with triple-knockdown of 
hnRNPA1/hnRNPA2/PTB in HEK-293 cells. hnRNPA1/A2 /PTB siRNAs and T7-tagged 
SRSF3 cDNA were co-transfected into HEK-293 cells. Cell lysates were prepared after 72 
hr, and knockdown and overexpression were verified by immunoblotting with monoclonal 
antibodies against the T7 tag (for SRSF3) and hnRNPA1, A2, and PTB, as well as tubulin as 
a loading control.  
(D) SRSF3 protein level was measured by Western blotting of HEK-293 and A172 cell lines.  
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Figure 2.8-12 
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2.8.12 Supplementary Figure 5. SRSF3 does not repress splicing of exon 9.  
 
(A) The indicated SRSF3 siRNA or control luciferase siRNA was co-transfected into HEK-
293 cells with the 9 SR minigene. Knockdown of SRSF3 was verified by immunoblotting, as 
shown in Fig. 5D. Minigene-specific transcript-level changes for PK-M1 and PK-M2 are 
shown. Labeled bands are as in Fig. 1C. Black asterisks indicate PstI-cleaved pre-mRNA. 
The red asterisk indicates a non-reproducible PCR artifact. % M1-included transcripts are 
indicated below the gel, with the following s.d: 2% (9S/luc), 1% (9S/SR3#1), 0.5% 
(9S/SR3#2).  
(B) Exon-9 duplication minigenes were co-transfected with increasing amounts of T7-tagged 
SRSF3 cDNA, as in Suppl. Fig. 4. Green and red boxes represent exons 9 and 10, 
respectively. A representative gel from a total of 3 replicates is shown. Labeled bands are as 
described in Fig. 1C and Suppl. Table 4. % M1 is indicated below the gel. 
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3 CHAPTER 3 
 
Rescue of PK-M Exon 9 inclusion by antisense oligonucleotides targeting PK-M in 
cancer cells 
 85 
3.1 Introduction 
Cancer cells preferentially use the glycolytic pathway with lactate generation, even in 
normal oxygen conditions (Vander Heiden et al., 2009). This metabolic feature is termed the 
Warburg effect. This expression of the type II isoform of the pyruvate-kinase-M gene 
(PKM2, referred to here as PK-M) has been shown to mediate the Warburg effect, and 
facilitate the in vivo proliferation of cancer cells (Christofk et al., 2008a).  
The PK-M gene consists of 12 exons; exons 9 and 10 are alternatively spliced in a 
mutually exclusive fashion to give rise to M1 and M2 isoforms, respectively (Noguchi et al., 
1986). As do other paralogs, pyruvate kinase-M (PK-M) catalyzes the final step in glycolysis 
to generate pyruvate and ATP from phosphoenolpyruvate (PEP) and ADP (Dombrauckas et 
al., 2005). Exons 9 and 10 each encode a 56-amino-acid segment that confers distinctive 
properties to the PK-M isozymes. PK-M1 is constitutively active, whereas PK-M2 is 
allosterically regulated by fructose-1,6-bisphosphate (FBP) levels and interaction with 
tyrosine-phosphorylated signaling proteins (Christofk et al., 2008b). 
 Consistent with the correlation between proliferation and PK-M2 expression, PK-M2 
is highly expressed in a broad range of cancer cells, whereas PK-M1 is predominantly 
expressed in terminally differentiated tissues (Christofk et al., 2008a; Clower et al., 2010). In 
particular, the mammalian target of rapamycin (mTOR) pathway, which is a central mediator 
of cellular growth and proliferation, transcriptionally induces PK-M2 expression through its 
downstream target, the transcription factor hypoxia inducible factor-1α (HIF-1α; (Sun et al., 
2011)).  
 Paradoxically, inhibition of PK-M2 kinase activity is required cancer-cell growth. 
This decreases carbon flux through the catabolic glycolytic pathway, allowing upstream 
 86 
intermediates to be shunted to anabolic pathways, facilitating proliferation (Christofk et al., 
2008a), and  detoxification of  reactive oxygen species (ROS; (Anastasiou et al., 2011)). 
Apart from allosteric regulation, PK-M2 kinase activity can be suppressed in many other 
ways. These include growth-signaling-mediated inhibition through the binding of 
phosphorylated tyrosine proteins to its allosteric pocket (Christofk et al., 2008b), direct 
phosphorylation at Y105 (Hitosugi et al., 2009), acetylation at K305 (Lv et al., 2011), and 
oxidation at C358 via ROS (Anastasiou et al., 2011). The multitude of avenues leading to 
PK-M2 inhibition underlies the importance of PK-M2 and glycolysis in tumorigenesis.  
PK-M2 has also been demonstrated to have critical functions beyond its kinase 
activity. In particular, PK-M2 has been shown to translocate into the nucleus and act as a co-
activator for HIF-1α (Luo et al., 2011), and β-catenin (Yang et al., 2011) in mediating 
transactivation of targets important for tumor growth and proliferation. In spite of the 
importance of PK-M2 in tumorigenesis, little is known regarding the alternative splicing of 
the PK-M gene that predominantly generates the PK-M2 isoform in cancer cells. 
 We and others have shown that the exon 9 inclusion that generates the PK-M1 
isoform is actively repressed in cancer cells via the well-characterized PTB/nPTB and 
hnRNPA1/A2 splicing repressors (Clower et al., 2010; David et al., 2010). We have also 
shown that critical cis-elements that mediate the PK-M2 dominant splicing pattern in cancer 
cells are located in the exons and have found a potent exon 10 ESE that recruits the splicing 
factor SRSF3 to exon 10 and activates it (Wang et al., 2011).  
 Because of the importance of PK-M2 as a cancer drug target, and in order to 
systematically find new splicing elements mediating the PK-M2 dominant splicing patterns, 
we conducted a systematic antisense oligonucleotide screen targeting endogenous PK-M 
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exons 9 and 10 to find new splicing cis-elements and to discover ASOs that switch the 
expression of the PK-M2 isoform back to PK-M1 isoform in cancer cells. 
 Short oligonucleotides were initially used to downregulate mRNA expression by 
homing to target mRNAs via Watson-Crick base pairing and inducing ribonuclease H 
mediated-degradation of nucleotide:RNA hybrids (Crooke, 2001). More recently, chemical 
modification has led to a class of nuclease-resistant ASOs that have high affinity for their 
RNA targets. A wide range of backbone-modified ASOs with differing chemical properties 
engineered for different applications include 2′-O-methyl phosphorothioate (2OMe) RNA, 
2-O-methoxyethyl (MOE) RNA, peptide nucleic acid (PNA), locked nucleic acid (LNA) and 
phosphorodiamidate morpholino (PMO) variants. These ASOs work by direct sequence-
specific annealing to target mRNA to either block splicing cis-elements, or block ribosome 
recruitment to inhibit translation (Muntoni and Wood, 2011; Opalinska and Gewirtz, 2002).  
 Our splicing ASO screen uncovered potent oligonucleotides that increase PK-M1 
inclusion in cancer cells. We show that the effective ASOs principally target a new ESE in 
exon 10, and treatment with these ASOs in a glioblastoma cell line induces apoptosis. We 
then show that this phenotype is caused by the ASO-mediated downregulated of PK-M2, 
highlighting the viability and therapeutic potential of PK-M2 as an ASO drug target. 
3.2 Results 
 
3.2.1 An exon-centered ASO screen uncovers potent oligonucleotides that increase 
PK-M1 inclusion in cancer cells 
 
Previously we reported that the critical cis-elements involved in the characteristic 
M2-dominant splicing pattern in proliferating cells are located in exons 9 and 10. To pinpoint 
the locations of these elements, we performed a systematic antisense oligonucleotide (ASO) 
walk along the entire length of PK-M exons 9 or 10. These ASOs contain 2′-O-methoxy-
ethyl ribose (MOE) phosphodiester backbones that allow them to bind to RNA targets with 
high affinity, while remaining resistant to both endogenous nucleases and the cleavage of 
resultant RNA:DNA hybrids by RNaseH (McKay et al., 1999; Monia et al., 1993). 48 and 45 
overlapping 15-mer ASOs were synthesized in 5-nt steps from 5’ to 3’ and are 
complementary to exons 10 and 9 respectively. The exon 10 ASOs cover the intron 9 region 
96 nt from exon 10, through the entire 167 nt exon 10 and until 42 nt into intron 10 (Fig 1A). 
Similarly, the 45 overlapping 15-mer Exon 9 ASOs cover the intron 8 region 77 nt from exon 
9, through the entire 167 nt exon 9, and end 16 nt downstream of exon 9 (Fig 2A). 
To examine the effects of individual ASOs on endogenous PK-M transcripts, we 
transfected each ASO with Lipofectamine into HEK-293 cells at a final concentration of 30 
nM and analyzed the splicing of the PK-M transcripts by radioactive RT-PCR 48 hours after 
transfection (Fig 1B and 2B). No strong increase in PK-M1 transcripts was observed when 
exon 9 ASOs were used; instead, some exon 9 ASOs led to an increase in the abundance of 
the exon 9-exon 10 double-skipped species (Fig 2B; species D), implying that these ASOs 
were interfering with the recognition of both exons. In contrast, some exon 10 ASOs strongly 
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increased the proportion of PK-M1 transcripts, with a concurrent increase in the amount of 
double-skipped species, suggesting that these ASOs were targeting ESEs in exon 10. The two 
most potent ASOs were the H11 and G7 ASOs. H11 targets the previously characterized 
exon 10 SRSF3 motif (Wang et. al. 2011) while the G7 ASO targeted a novel 15 nt region in 
the middle of exon 10. Because of the strong effect of G7 on PK-M splicing, we decided to 
characterize the G7 ASO and its target 15 nt region (termed as the G7 region). 
3.2.2 The G7 ASO targets a novel activation region of PK-M exon 10 
 
To map the enhancer elements present in the G7 region, we took advantage of the 
high sequence identity between exon 9 and 10, and duplicated the entire exon 10 G7 region 
into the corresponding region in exon 9 (Fig 3A). We also split the G7 region  
and duplicated only the first 7-nt subregion (termed the 10F region) and the last 8-nt 
subregion (termed the 10B region). Duplication of the exon 10 G7 region increased exon 9 
inclusion (Fig 3B, lanes 1-4). However, only the duplication of the B7 region, but not the F7 
region increased exon 9 inclusion, to an even greater extent than when the entire G7 region 
was duplicated (Fig 3B, compare lanes 5-6 with lanes 7-8). This suggests that the G7 region 
is a bona fide exon 10 ESE.  
3.2.3 The G7 ASO interferes with exon 10 definition 
  
To characterize the mechanism of action of the G7 ASO, we transfected exon 10 
ASOs G7, G6 and an exon 9 ASO, B7, that targets the corresponding G7 region in exon 9, 
together with the previously characterized PK-M wildtype, exon 9 duplication, and exon 10 
minigenes (Fig 3C). The wild-type minigene consists of the portions of the flanking exons 8 
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and 11 (Fig 3D), and the complete genomic region between both exons, whereas the 
duplication constructs have exon 10 (Fig 3E) or exon 9 (Fig 3F) entirely duplicated into the 
native exon 9 or exon 10 location, respectively. 
 As expected, G7 and G6 ASOs increased %M1 inclusion from the wild-type 
minigene transcripts (Fig 3D, lanes 3-6). The G7 ASO increased %M1 inclusion to a greater 
extent than G6, presumably because it completely targets the 10B region as opposed to G6, 
which targets only part of the region (Fig 3C). In agreement with RT-PCR of endogenous 
RNA, the exon 9 ASO B7 had no effect on minigene %M1 inclusion (Fig 3D, lanes 7-8). 
Co-transfection of the G7 and G6 ASOs with the exon 10 duplication minigene led to 
a large increase in double-skipped species (Fig 3E, lanes 3-6), strongly suggesting that ASOs 
that target the G7 region act mainly by interfering with exon 10 activation, allowing 
spliceosomal components to be recruited to exon 9. However, transfection of G7 and G6 
ASOs with the exon 9 duplication minigene also led to a slight increase in PK-M1 inclusion 
(Fig 3F, lanes 3-6). Since the B7 ASO did not increase PK-M1 inclusion from the exon 9 
duplication minigene and instead reduced it (Fig 3F, Lanes 7-8) we ruled out the possibility 
that the G7/G6 ASOs were binding to the homologous exon 9 region. We hypothesized that 
there was a second site along the genomic region that could be targeted by G7.  
3.2.4 The second binding site for the G7 ASO is located in PK-M intron 9. 
 
Alignment of the G7 region with the PK-M exon 8 – 11 genomic region revealed a 
highly homologous region in intron 9 (Fig 4A). To interrogate the region for enhancer 
activity, we performed a supplementary intron 9 walk centered on the G7 homologous 
region. Nine overlapping ASOs targeting this region were synthesized, and we found that the 
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intron 9 B12 ASO strongly increased %M1 inclusion. This B12 ASO targeted exactly the 
G7-homologous region in intron 9, suggesting that this B12 region could also be an exon 10 
enhancer element or exon 9 silencing element.  
3.2.5 The exon 10 G7 region is more important for ASO-mediated PK-M1 inclusion 
 
Because B12 is nearly identical to the G7 ASO, B12 could potentially also target the 
exon 10 G7 region (3 mismatches between the B12 and G7 target regions). To weigh the 
importance of the G7 and B12 regions in the G7 ASO-mediated recovery of endogenous PK-
M1 transcripts, we made combinatorial minigene mutations that elminated the G7 or B12 
binding sites, and determined the effect of these ASOs on the mutant minigenes. Three 
mutants were generated (Fig 4C). We mutated the exon 10 G7 region by duplicating the 
corresponding exon 9 region (termed the 9G7 construct); we made a 15 nt deletion in intron 9 
that removed the B12 target region (termed the dB12 construct), and we introduced both 
mutations in the same minigene (termed the DMGB construct). The 9G7 minigene gave a 
slight increase in minigene PK-M1 inclusion (Fig 4D, lanes 3-4), suggesting that the 
duplicated exon 9 region contains enhancer elements, albeit weaker than the elements found 
in the exon 10 G7 region. There was a slight increase in exon 9-exon 10 doubly-spliced 
transcripts from dB12, with a decrease in the amount of PK-M1 transcripts (Fig 4D, lanes 5-
6), suggesting that this region is involved in repressing the splicing of exon 9 to exon 10, and 
is not directly involved in the repression of exon 9 per se. Co-transfection of the B12 ASO 
with the three mingenes revealed that B12-mediated PK-M1 inclusion is largely dependent 
on the integrity of both the exon 10 G7 region (Fig 4D, lanes 13-18) and its intron 9 own 
binding site, as removal of both binding sites largely abrogated PK-M1 inclusion (Fig 4D, 
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lanes 16-18). In contrast, only the loss of the G7 binding site largely abrogated G7-mediated 
PK-M1 inclusion (Fig 4D, lanes 7-12). When both G7 and B12 binding sites were removed, 
G7-mediated PK-M1 inclusion was then completely abrogated (Fig 4E). The above results 
suggest that the G7 ASO largely mediates PK-M1 inclusion through the cognate exon 10 G7 
region, though it could exert smaller effects through its supplementary intron 9 B12 binding 
region.  
3.2.6 G7 ESE region centered ASO microwalks 
 
To find the optimal ASO that targets the exon 10 G7 region, we performed an ASO 
microwalk along both regions (Fig 5A). Overlapping 15-nt ASOs targeting the G7 ESE were 
synthesized in 1 nt steps in the 5’-3’ direction. A total of 20 ASOs were synthesized for the 
G7 regions (Fig 5A), and transfected into HEK-293 cells at a final concentration of 60 nM. 
We found that the C7 ASO was the most potent among the candidate microwalk ASOs, in 
terms of increasing endogenous PK-M1 transcript abundance (Fig 5B). This ASO targeted 
the B7 region to a similar extent as G7.  To objectively compare the performance of ASOs 
targeting the G7 region and the previously characterized SRSF3 regions, we performed side-
by-side ASO transfections at different doses, with final concentrations of 60 and 120 nM. We 
found that both G7 ASOs was the most potent in eliciting PK-M1 transcript inclusion, 
compared to the H11 and C7 ASOs (Fig 5C, compare lanes 3-6 with lanes 7-14), with H11 
performing slightly better than C7. We also found that the effects of combining two ASOs 
were not additive (Fig 5C, lanes 15-18). Since targeting the G7 region gave the most %M1 
inclusion, we decided to test the G7 or C7 ASOs in other cancer cell lines. 
3.2.7 ASOs targeting the exon 10 G7 region induce apoptosis in glioblastoma cells. 
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Because normal brain tissue mainly expresses PK-M1, while a characteristic splicing 
switch to PK-M2 occurs during tumorigenesis (Bluemlein et al., 2011; Clower et al., 2010), 
we decided to focus on glioblastoma cells. In addition, due to mutation of the PTEN tumor 
suppressor, there is a characteristic overactivation of the mTOR pathway in glioblastoma 
cells (Verhaak et al., 2010), which makes them susceptible to glucose-withdrawal induced 
cell death (Choo et al., 2010).Thus, targeting of PK-M2 and by extension, the glycolytic 
pathway, could potentially be a viable strategy for glioblastoma treatement. Lastly, because 
there is generally a higher basal level of PK-M1 in glioblastoma cells (Clower et al., 2010), it 
might be easier to effect an ASO-mediated splicing switch back to the PK-M1 isoform.  
 We first tested the G7 and C7 ASOs in the PTEN-mutant A172 and U87-MG 
glioblastoma cell lines, transfecting at final concentrations of 60 nM and 120 nM (Fig. 6A). 
As expected, there was a dose-dependent increase in PK-M1 inclusion in these cell lines, 
with G7 ASO performing better than C7 ASO. In addition, there was greater %M1 inclusion 
in these cells, compared to HEK-293 cells. We also noticed that transfecting these ASOs into 
both of these cell lines induced apoptosis as early as 24 hours after transfection, even at the 
relatively lower dose (Fig 6B). Because C7 was less effective at inducing apoptosis, 
compared to G7, we used this ASO to facilitate the downstream analysis of these cells. 
We found that upon transfection of C7 ASO, expression of PK-M2 protein was 
downregulated, concurrent with the appearance of cleaved PARP as an apoptotic marker (Fig 
6B). Apoptosis was only partially rescued upon the addition of the exogenous FLAG-tagged 
mouse PKM2 cDNA into A172 cells; however, the FLAG signal was also decreased after 48 
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hours, implying that the C7 ASO might interfere with translation of the mouse PKM2 cDNA, 
presumably by binding to the completely homologous mouse cDNA region (Fig. 6B).  
3.2.8 ASO-mediated apoptosis is caused by the downregulation of endogenous PK-M2 
expression in glioblastoma cells.  
 
Upon ASO transfection, there was; 1) an increase in PK-M1 inclusion; 2) an increase 
in the abundance of double-skipped (Skp) mRNA species; and 3) a decrease in PK-M2 
inclusion. We wanted to find out which event was responsible for inducing apoptosis in 
glioblastoma cells. To do so, we made stable A172 cell lines that express human PK-M1 or 
human Skp isoform in a doxycyclin(dox)- dependent manner (Fig 6C), or knocked down PK-
M2 expression using siRNA, and probed for the appearance of apoptotic markers after 48 
hours (Fig 6D). We found that apoptosis was observed upon siRNA transfection, but not 
upon dox-induction of PK-M1 or Skp isoforms (Fig 6D). This implies that the ASO-mediated 
apoptosis was due to the downregulation of PK-M2 expression in glioblastoma cells. 
3.3 Discussion 
We have performed a systematic ASO screen of exons 9 and 10, and have discovered 
potent ASOs that rescue the inclusion of PK-M1 in cancer cells. We also show that these 
ASOs are effective in glioblastoma cells, and induce apoptosis upon ASO treatment. Finally, 
we show that it is the downregulation of PK-M2 expression that causes this apoptosis.  
 
3.3.1 Apoptotic effects of PK-M2 isoform switching in glioblastoma cells 
 
Glioblastomas are known to exhibit a high rate of glycolysis, even in normal oxygen 
conditions (Clower et al., 2010). Consistent with this phenomenon, the splicing profile of 
glioblastoma cell lines, as with other cancer cell lines, is PK-M2 dominant. In particular, 
since the splicing profile of PK-M in normal brain tissue is PK-M1 dominant (Bluemlein et 
al., 2011), there is a splicing switch from PK-M1 to PK-M2 during gliomagenesis. In 
addition, because it is known that glioblastoma cells freely take up ASOs in situ (Dean et al., 
1996), and that minimally-invasive methods of ASO delivery into the central nervous system 
(CNS) via intrathecal means  (Belverud et al., 2008), ASO-mediated PK-M1 rescue could be 
a viable strategy in the treatment of glioblastoma multiforme.  
We observed that ASO treatment led to apoptosis of glioblastoma cell lines. Because PK-M2 
is a rate-limiting glycolytic enzyme, targeting PK-M2 might target the entire glycolytic 
pathway, leading to apoptotic effects as observed by glucose withdrawal in glioblastoma 
cells in vitro (Jelluma et al., 2006). The replacement of PK-M2 in tumor cells with PK-M1 
could lead to a shunting of metabolites into the mitochondria (Christofk et al., 2008b), 
phenocopying the apoptotic phenotype that is displayed by glioblastoma cells after treatment 
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with dichloroacetic acid (DCA), as a result of increased ROS production (Bonnet et al., 2007; 
Michelakis et al., 2010). Lastly, because PK-M2 also functions as a co-activator of HIF-1 
(Luo et al., 2011) and β-catenin (Yang et al., 2011) transactivation, targeting the expression 
level of PK-M2, as opposed to inhibiting its kinase function, might also interfere with anti-
apoptotic (Sendoel et al., 2010) and pro-proliferative functions mediated by these factors.  
 
3.3.2 Translational inhibition of PK-M2 mRNA 
 
We observed that restoring the level of PK-M2 in ASO-treated cells by exogenous addition 
of mouse PK-M2 cDNA was not sufficient to fully rescue the observed apoptotic phenotype. 
This is due to an ASO-dependent decrease in the amount of protein expressed from the 
mouse cDNA. This is a favorable outcome of ASO treatment, in that residual PK-M2 
transcripts are translationally inhibited by the ASO, leading to a reinforcement of the PK-M2 
to PK-M1 splicing switch at the protein level. As ASOs are also known to bind to mRNA and 
interfere with the recruitment of the translational machinery (Muntoni and Wood, 2011), 
further work must be done to confirm the apparent ASO-mediated translational inhibition of 
PK-M2 mRNA.  
 
3.3.3 Mechanism of ASO-mediated PK-M2 to PK-M1 switch  
 
How does blocking the activation of the exon 10 G7 region lead to an activation of PK-M 
exon 9? Although this could be explained in terms of 3’ss competition, in which the loss of 
exon 10 definition leads to increased recognition of the exon 9 3’ss by the splicing 
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machinery, it is not known at present which splicing factor(s) bind to this G7 ESE. Because 
ASOs targeting G7 also lead to inhibition of translation, the splicing factor binding to this 
region could be part of a RNP e involved in downstream post-splicing processes, such as 
mRNA transport, translation and stability.  
 
3.3.4 Failure of exon 9 ASOs to rescue PK-M1 inclusion 
 
Because we have demonstrated that exon 9 is enriched in ESS elements in the context of 
cancer cells, it was surprising that not one exon 9 ASO tested could rescue PK-M1 inclusion, 
as some ASOs were expected to block an ESS and facilitate the recognition of exon 9 by the 
splicing machinery. We speculate that ASO binding to the putative ESS could interfere with 
the second splicing step, i.e the ligation of exon 8 and exon 9, leading to the use of the 
alternate exon 11 3’ss and resulting in the observed increase in abundance of double-skipped 
RNA species. Another possibility is that distal regions (i.e, sequences that are outside of the 
ASO screening region) could be involved in exon 9 silencing, which would not have been 
revealed in the previous exon-duplication and swap experiments (Wang et al., 2011).  
 
3.3.5 Use of ASOs in mouse models of glioblastoma 
 
Because the ASOs we have screened are potent enough to switch the PK-M splicing profile 
of glioblastoma cells from PK-M1 to PK-M2 in vitro, the next step to demonstrate the 
therapeutic potential of these ASOs will be to test these ASOs in the context of allogenic 
xenograft or orthotopic models of glioblastoma. 
3.4 Experimental Procedures 
 
3.4.1 Cells and transfections 
 
HEK-293, U87-MG and A172 cells were obtained from ATCC and grown in DMEM, 
supplemented with 10% (v/v) FBS, penicillin and streptomycin, at 37 °C and 5% CO2. 5 µg 
of minigene plasmid per 10-cm dish, or 1 µg per 6-cm dish, was transiently transfected using 
Lipofectamine 2000 (Invitrogen). For ASO transfections, 4x106 cells were first plated, and 
then ASO transfections were performed using a ASO:Lipofectamine 2000 ratio of 25 pmol:1 
µl. Total RNA and protein from transfected cells was harvested after 48 hr. For doxycyline 
induction, doxycyline was added to the media at a final concentration of 100 ng/ml for 3 days 
before harvest.  
3.4.2 Oligonucleotide synthesis 
Synthesis and purification of chimeric 2′-O-methoxyethyl–modified oligonucleotides 
with a phosphodiester backbone were performed at ISIS Pharmaceuticals using an Applied 
Biosystems 380B automated DNA synthesizer (Applied Biosystems, Foster City, California, 
United States) as described previously (Hua et. al. 2011). The oligonucleotides were 
dissolved in water.  
3.4.3 RNA interference 
 
4 siRNAs targeting exon 10 of human PKM2 were obtained from Sigma Genosys, and 
have the sense-strand sequences 5’-CCAUAAUCGUCCGCACCAA-3’ (M2si1), 5’-
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CAUCUACCACUUGCAAUUA-3’ (M2si2), 5’-CCGUGGAGGCCUCCUUCAA-3’ (M2si3) 
and 5’CUUGCAAUUAUUUGAGGAA-3’ (M2si4). 4x106 A172 cells in 6-well plates were 
transfected with 400 pmol of siRNA duplex using Lipofectamine 2000 (Invitrogen). Cells 
were harvested 48 hr later.  
3.4.4 Retrovirus transduction 
 
To generate FLAG-tagged mPKM1 or mPKM2 overexpressing transductants, A172 
cells were infected with pLHCX-mPKM1 or mPKM2 retrovirus (Christofk et al) and selected 
in 300 µg/ml of hygromycin for 2 weeks. To generate tet-on cell lines that overexpress 
human PKM1 (A) or human Skp (D) isoforms in a doxycylin-dependent manner, A172 cells 
were first infected with MSCV-rtTA-hygro virus, and selected in hygromycin for 2 weeks. 
Human PKM1 and Skp cDNA were amplified from A172 cells transfected with C7 ASO 
using the following primer pair hPKT7cDNAF (5’-
GGGGAACTCGAGATGGCTTCTAGGATGGCATCGATGACAGGTGGCCAACAGATG
GGCATGTCGAAGCCCCATAGTGAAGCCG-3’) and hPKT7cDNAR (5’- 
GGGGAAGAATTCTCACGGCACAGGAACAACACGCATG-3’) with Phusion High-
Fidelity DNA Polymerase (Finnzymes). The resultant amplicons containing the T7 tag were 
then gel-purified and cloned between the EcoRI and XhoI sites of the retroviral TtiGP 
plasmid. Plasmids were sequenced to confirm their identities. A172-rTT cells were then 
infected with TtiGP-PKM1 or TtiGP-Skp virus and selected with 100 µg/ml of puromycin 
for 3 days. 
 
3.4.5 Immunoblotting 
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Cells were lysed in SDS, and total protein concentration was measured by the 
Bradford assay. 30 µg of total protein was separated by SDS-PAGE and transferred onto 
nitrocellulose, followed by blocking with 5% (w/v) milk in Tris-buffered saline with Tween-
20, probing with the indicated antibodies, and visualization by enhanced chemiluminescence 
(Roche). Primary antibodies were: β-tubulin (Genscript rAb, 1:5000); PK-M2 (Cell 
Signalling Technology, rAb, 1:2000); PARP (Cell Signalling Technology, rAb 1:1000); 
FLAG (Sigma, mAb 1:5000) and PK-M1 (rabbit, 1:2000 (Christofk et al., 2008b)). 
Secondary antibodies were goat anti-mouse or anti-rabbit HRP conjugates, 1:20,000 (Bio-
Rad).  
 
3.4.6 Minigene construction 
 
DNA oligonucleotides were obtained from Sigma Genosys. The PK-M2 minigene 
was constructed by amplifying a 6.4-kb PK-M exon 8-11 fragment from human genomic 
DNA (Promega) using Phusion High-Fidelity DNA Polymerase (Finnzymes) and primers 
PKMinigeneF (5’-GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3’) and 
PKMinigeneR (5’-GGGGAACTCGAGCTAGACATTCATGGCAAAGTTCACC-3’). The 
product was then digested and cloned between the BamHI and XhoI sites of pcDNA3.1+ 
(Invitrogen). For exon duplication and intron deletion constructs, the upstream KpnI site 
1552 nt downstream of exon 8 was removed by a 1-nt deletion, and an EcoRV restriction site 
was generated 90 nt upstream of exon 9 by a 2-nt insertion to create a modified wild-type 
minigene. To generate the 10G7, 10B7 and 1010F7 constructs, modified Exon 9 fragments 
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were generated by annealing the following oliognucleotides 10G7F (5’- 
CCCTAAACCTTACAGATAGCTCGTGAGGCTGAGGCAGCCATGTTCCACCGCAAG
CTGTTTGAGGAACTCCGCCGAGCCTCAAGTCACTCCACAGACCTCATGGAAGCC
AT-3’), 10F7F (5’-
CCCTAAACCTTACAGATAGCTCGTGAGGCTGAGGCAGCCATGTTCCACCGCAAG
CTGTTTGAGGAACTTGTGCGAGCCTCAAGTCACTCCACAGACCTCATGGAAGCC
AT-3’), 10B7F (5’- 
CCCTAAACCTTACAGATAGCTCGTGAGGCTGAGGCAGCCATGTTCCACCGCAAG
CTGTTTGAAGAACTCCGCCGAGCCTCAAGTCACTCCACAGACCTCATGGAAGCC
AT-3’) with Exon 9Rev oligo (5’-
CCCTTAGGGCCCTACCTGCCAGACTCCGTCAGAACTATCAAAGCTGCTGCTAAAC
ACTTATAAGAAGCCTCCACGCTGCCCATGGCC ATGGCTTCCATGAGGTCTG -3’) 
and amplifying using Ex10ADupF (5’-
TTCCCCATTCTGTCTTCCCATGTGTTGTGTCTCGTTTTTTTCCTCCTCCTTCCCTCTT
CCTTGCCCCCTCTTCCCCTAAACCTTACAG-3’) and  Ex10ADupR (5’-
AGTGTTACCTGCCCTTAGGGCCCTAC-3’). The 106-nt oligonucleotide carries mutations 
that duplicate specific stretches of exon 10 over the corresponding region of exon 9. Another 
fragment was amplified from the wild-type minigene using the following primer pairs: 
Ex10BF: 5’-GTAGGGCCCTAAGGGCAGGTAACAC-3’ and RKpnI (5’-
GGGGAAGGTACCACTGAGCAGGGCATT-3’). Both fragments were then gel-purified, 
and subjected to a second OE PCR reaction using the end primers FEcoRV (5’-
GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3’) and RKpnI.  
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To generate the 9G7 minigene construct, a modified exon 10 fragment was constructed by 
annealing 9G7F (5’- 
ATGTTGCTCCCCTAGATTGCCCGTGAGGCAGAGGCTGCCATCTACCACTTGCAAT
TATTTGAAGAACTTGTGCGCCTGGCGCCCATTACCAGCGACCCCACAGAAGCCA
C-3’) with Exon 9 Rev (5’-
CGCTGCCGCCTCCTACCTGCCAGACTTGGTGAGGACGATTATGGCCCCACTGCAG
CACTTGAAGGAGGCCTCCACGGCACCCACGGCG GTGGCTTCTGTGGGGTCGCT-
3;) and amplifying using Ex9ADupF (5’-TGGACGGATGTTGCTCCCCTAG-3’) and 
Ex9ADupR (5’-
GGTACCACTGAGCAGGGCATTCCAGGGAGCCGCTGCCGCCTCCTAC-3’). The 108-
nt oligonucleotide carries mutations that duplicate specific stretches of exon 9 over the 
corresponding region in exon 10. Another fragment was amplified from the wild-type 
minigene using the following primer pairs: FEcoRV and Ex9BR (5’-
GTAGGGCCCTAAGGGCAGGTAACAC-3’). Both fragments were then gel-purified and 
subjected to a second OE PCR reaction using the FEcoRV and RKpnI primers.  
To generate the dB12 mutant, two fragments were generated from the wildtype minigene 
construct, using the following primer pairs: FEcoRV and PKMdelB12R (5’ 
TGCCCTGCCATGACCTCCCAGACGAGAAGAGGCTCTGTGCCCAG-3’) and 
PKMdelB125 (5’- ACA GAG CCT CTT CTC GTC T GG GAG GTC ATG GCAGGGCAG-
3’). To generate the DMGB double mutant, the same two fragments were generated from the 
9G7 minigene.  Both fragments were then gel purified and subjected to a second OE PCR 
using FEcoRV and RKpnI. All generated fragments were then cloned between the EcoRV 
and KpnI sites of the modified wild-type minigene plasmid.  
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3.4.7 RT-PCR 
 
2-5 µg of total RNA was extracted from cell lines using Trizol (Invitrogen). 
Contaminating DNA was removed with DNAase I (Promega). Reverse transcription was 
carried out using ImPromp-II reverse transcriptase (Promega). Semiquantitative PCR using 
Amplitaq polymerase (Applied Biosystems) was performed by including [α-32P]-dCTP in the 
reactions. The human-specific primer sets used to amplify endogenous transcripts anneal to 
PK-M exons 8 and 11, and their sequences are: hPKMF: 5’-
AGAAACAGCCAAAGGGGACT-3’; hPKMR: 5’-CATTCATGGCAAAGTTCACC-3’. To 
amplify minigene-specific transcripts, the forward primer was replaced with a primer 
annealing to the pcDNA3.1(+) vector, pcDNAF: 5’-TAATACGACTCACTATAGGG-3’. 
After 28 amplification cycles for minigene-derived transcripts, and 27 cycles for endogenous 
transcripts, the reactions were divided into two aliquots for digestion with PstI (New England 
Biolabs) or undigested control. The products were analyzed on a 5% native polyacrylamide 
gel, visualized by autoradiography, and quantified on a FLA-5100 phosphoimager (Fuji 
Medical Systems) using Multi Gauge software Version 2.3. The % M1 mRNA in 
endogenous transcripts was calculated using the GC-content-normalized intensities of the top 
undigested band (M1, A), the bottom two digested bands (M2, B1 B2) in the PstI-digest lanes 
and the double skipped species (D), if detectable. The % M1 mRNA from minigene-
transcripts was calculated using the GC-content-normalized intensities of the top undigested 
band (a, M1) and other higher-mobility digested bands corresponding to M2 and its variant 
species (b – g, as described above) in the PstI-digest lanes. All the PCR products were gel-
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purified, cloned, and sequenced to verify their identities.
3.5 Figure Legends 
Figure 3.5-1 
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3.5.1 Fig 1. Initial ASO walk along PK-M exon 10. 
  
(A) Schematic representation of the initial ASO walk along exon 10 and flanking regions. 
Exon 10 is indicated by the red box, while flanking regions (~100 bp of introns 8 and 9) are 
represented by the thick line. Stacked thin lines above the box represent an individual ASO. 
Names of the ASOs are indicated at the top of each stack, from bottom to top. Their 
approximate binding sites are aligned with the exon 10/intron 8/intron 9 diagrams. (B) 
Radioactive RT-PCR and restriction digests of endogenous PK-M transcripts in HEK-293 
cells (as in Clower et. al. 2009) after ASO transfection at a final concentration of 30 nM. 
RNA was harvested from cells 48 hours after transfection. The identity of the transfected 
ASO is indicated at the top. cDNAs and fragements from endogenous mRNAs are indicated 
on the left. Because PK-M2 is sensitive to PstI digestion (indicated as “P”), the uncut 398 nt 
A fragment corresponds to full-length PK-M1. B1 (213 nt) and B2 (185 nt) are 3’ and 5’ PstI 
digested fragments of the full-length PK-M2 B (398 nt). D (271 nt) is a PstI resistant cDNA 
that lacks both exons 9 or 10. Both ASO G7 and H11 show the highest amount of M1 
inclusion upon transfection.  
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Figure 3.5-2 
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3.5.2 Fig 2. Initial ASO walk along PK-M exon 9.  
 
(A) Schematic representation of the initial ASO walk along exon 9 and flanking regions. 
Exon 9 and its flanking regions (~100 bp of introns 9 and 10) is indicated by the green box 
and thick line, respectively. Stacked thin lines above the box represent an individual ASO. 
Names of the ASOs are indicated at the top of each stack, from bottom to top. Their 
approximate binding sites are aligned with the exon 9/intron 9/intron 10 diagrams. (B) 
Radioactive RT-PCR and restriction digest of endogenous PK-M transcripts in HEK-293 
cells after ASO transfection at a final concentration of 30 nM. RNA was harvested from cells 
48 hours after transfection. The identity of the transfected ASO is indicated at the top. 
cDNAs and fragments from endogenous mRNAs are indicated on the left. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109 
Figure 3.5-3 
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3.5.3 Fig 3. Characterizing the G7 ASO target region.  
 
(A) Schematic of method used to duplicate the exon 10 G7 region. The indicated exon 9 
(green) nucleotides at the top were mutated to the corresponding exon 10 (red) sequences. 
The 10G minigene duplicates the entire G7 region into exon 9, the 10F minigene duplicates 
the first 8 nt, and the 10B minigene duplicates the last 7 nt of G7. The ASOs that target G7 
and flanking regions are indicated below.  (B) The G7 motif is an exon 10 ESE. Mutant 
minigenes were analyzed by transient transfection into HEK-293 cells, followed by 
radioactive RT-PCR and restriction digests, as in Fig. 1. To amplify minigene transcripts, a 
primer annealing to a vector-specific sequence, pcDNAF, was used, as in Wang et. al. 2011. 
Constructs from (A) are labeled at the top. Labeled bands are indicated in lower case on the 
left and right, with important bands in blue font. %M1 is indicated at the bottom. Bands are 
as follows: uncut M1 fragment (a, 481 nt); uncut M2 fragment (b, 481 nt); PstI-cleaved M2 
5’ fragment (b2, 268 nt); PstI-cleaved M2 3’ fragment (b3, 213 nt); spliced mRNA that skips 
both exons 9 and 10 (d, 314 nt); an exon 9 – exon 10 doubly-included mRNA are indicated 
on the left (f, 648 nt). This band is sensitive to PstI (f1, 435 nt) (C) Schematic of ASOs and 
their binding sites used for minigene experiments in (D). G6 and G7 ASOs target exon 10 
and are indicated at the bottom. The B7 ASO indicated at the top targets the exon 9 region 
that corresponds to exon 10 G7. (D),(E),(F) Minigene transcript level changes as a result of 
ASO co-transfection in HEK-293 cells. ASOs were transfected at a final concentration of 30 
nM. The wild-type (D), exon 10 (E) duplication, and exon 9 (F) duplication (Wang et. al. 
2011) minigenes, together with the identity of ASOs, are indicated at the top. Labeled bands 
are indicated in lower case on the left, with important bands in blue font. %M1 is indicated at 
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the bottom. The exon 10 – exon 10 doubly-included mRNA in (E) expressed from the exon 
10 Dup minigene is indicated on the left (g, 648 nt). 
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Figure 3.5-4 
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3.5.4 Fig 4 A second binding site for G7 ASO.  
 
(A) Schematic of the supplementary intron 9 ASO walk centered on an intron 9 region (in 
blue letters) that is nearly homologous to the G7 ASO binding site, indicated at the bottom. 
Stacked lines indicate ASOs and their binding sites are aligned with intron 9. ASO names are 
indicated on the left. (B) Radioactive RT-PCR and restriction digest of endogenous PK-M 
transcripts in HEK-293 cells (as in Clower et. al. 2009) after ASO transfection at a final 
concentration of 30 nM. RNA was harvested from cells 48 hours after transfection. The 
identity of the transfected ASO is indicated at the top. cDNAs and fragements from 
endogenous mRNAs are indicated from on the left. (C). Schematic of minigene mutants used 
in (D) and (E). 9G7 has the G7 ASO binding site in exon 10 removed and replaced by the 
corresponding region in exon 9. dB12 contains a 15-nt deletion of the intron 9 region targeted 
by ASO B12 in (A). DMGB contains both the mutations. (D),(E) Minigene transcript level 
changes as a result of ASO co-transfection in HEK-293 cells. ASOs were transfected at a 
final concentration of 30 nM. ASOs and minigenes in (C) are indicated at the top %M1 is 
indicated at the bottom, and bands are indicated on the left. 
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Figure 3.5-5 
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3.5.5 Fig 5. G7-centered ASO microwalks.  
 
(A),(C) Schematic representation of the 1 nt ASO microwalk along exon 10. Red letters 
indicate the exon 10 sequence. Stacked thin lines represent an individual ASO. Names of the 
ASOs are indicated on the left, from the bottom to top. Their approximate binding sites are 
aligned with the exon 10/intron 8/intron9 diagrams. The G7 region and the previously 
described SRSF3 ESE (Wang et. al. 2011) are indicated by rectangles in (A) and (C), 
respectively. (B),(D) Radioactive RT-PCR and restriction digest of endogenous PK-M 
transcripts in HEK-293 cells after ASO transfection at a final concentration of 30 nM. RNA 
was harvested from cells 48 hours after transfection. The identity of the transfected ASO is 
indicated at the top. cDNAs and fragments from endogenous mRNAs are indicated on the 
left. (E) Dose dependent effects of C7, G7 and H11 ASOs in 293 cells. Radioactive RT-PCR 
and restriction digest of endogenous PK-M transcripts in HEK-293 cells after ASO 
transfection at a final concentration of 60 and 120 nM. RNA was harvested from cells 48 
hours after transfection. The identity of the transfected ASO is indicated at the top. cDNAs 
and fragments from endogenous mRNAs are indicated on the left. %M1 is indicated at the 
bottom. For combination experiments, each ASO was transfected at 60 nM each, for a final 
total ASO concentration of 120 nM.  
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Figure 3.5-6 
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3.5.6 Fig 6. Effects of ASOs on glioblastoma cells.  
 
(A) Dose-dependent effects of C7 and G7 ASOs in A172 and U87-MG glioblastoma cells. 
Radioactive RT-PCR and restriction digests of endogenous PK-M transcripts from the 
indicated cell lines, 48 hours after transfection of the indicated ASOs at final concentrations 
of 60 or 120 nM. The control ASO (Ctrl) is an ASO targeting exon 7 of the SMN2 gene (Hua 
et. al. 2008). %M1 is indicated at the bottom. (B) Immunoblot analysis of A172 cells or 
A172 cells stably transduced with mouse PK-M2 cDNA, transfected with C7 or Control 
ASOs at a final concentration of 60 nM. C7-transfected  cells were harvested 24 and 48 hours 
after transfection, while control cells were harvested after 48 hours. Antibodies used are 
indicated on the left. (C) Immunoblot analysis of A172 cells stably transduced with rtTA and 
doxycycline (dox)-inducible human PK-M1 or human Skp cDNA. Cells were harvested 48 
hours after addition of doxycylin. Antibodies used are indicated on the left. (D) Immunoblot 
analysis of A172 cells transfected with 4 different PK-M2 siRNAs or A172 cells with dox-
induced PK-M1 or Skp as in (C). Antibodies used are indicated on the left. 
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4 Chapter 4. Conclusions and Perspectives 
 
4.1 Summary of conclusions 
I have analyzed the alternative splicing of the mutually exclusive (ME) PK-M gene in 
cancer cells. I have demonstrated that exons 9 and 10 are repressed and activated, 
respectively, in cancer cells, and the elements involved in both processes are located mainly 
in the exons. These elements are critical in maintaining the PK-M2 dominant splicing pattern 
in proliferating and cancer cells. Through sub-exonic duplications, I have isolated a potent 
ESE in exon 10 and demonstrated that SRSF3, a known splicing factor, is its cognate 
activator. Making use of the discovery that critical splicing cis-elements are in the ME exons, 
I conducted an ASO walk along both exons, and discovered potent ASOs targeting exon 10 
that switch the splicing of PK-M in cancer cells from a PK-M2 dominant pattern to a PK-M1 
dominant pattern. I then tested the ASOs in glioblastoma cells and found that these ASOs 
induced apoptosis.  
4.2 Future directions  
Even though the mechanism PK-M alternative splicing is still incompletely 
understood, these discoveries represent an advance in the understanding of PK-M splicing in 
cancer cells. However, there are more specific areas of PK-M splicing that have yet to be 
explored, which I will outline below. 
4.2.1 Analysis of PK-M splicing in a PK-M1 dominant system 
 
All of the analyses of PK-M splicing were done in cancer cells, which predominantly 
express PK-M2. In order to fully understand the splicing switch from terminally 
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differentiated cells to cancer cells, an analysis of PK-M splicing must also be done in a PK-
M1 dominant system. These cell lines exist, specifically the C2C12 myoblast differentiation 
system (Clower et al., 2010; David et al., 2010). Minigene constructs could be transfected 
into these cells when they are still proliferating, and induced to differentiate, before 
harvesting to analyze minigene splicing. 
4.2.2 Uncovering exon 9 ESSs 
 
Although the ASO walks and sub-exonic duplications have uncovered exon 10 
enhancer elements, exon 9 exonic silencers have yet to be discovered. The exon 9 ASOs 
could have interfered with exon 9 splicing (as discussed in Chapter 3), but systematic exon 9 
sub-duplications have yet to be done. The other problem is that the sub-exonic duplication 
approach is dependent on the duplicated region having a weaker or opposite type of element, 
which further confounds analysis and/or discovery.  
4.2.3 Prevention of exon 9 and exon 10 double splicing 
 
 The predominant species from the exon 10 duplication minigene is the singly spliced PK-M2 
isoform. This is unexpected, because it has been shown that exon 10 is strongly activated in 
cancer cells, and hence, if there were no repression of exon 9 and exon 10 double splicing, 
the predominant species should be the exon 10-exon 10 double-spliced isoform. Mutation of 
the B12 intron 9 region (Chapter 3) has also led to some double splicing. This implies that 
there could be elements in the flanking introns that prevent the double splicing of exon 9 to 
exon 10. Clearly, minigene mutagenesis analysis should be carried out to find elements that 
when deleted or mutated, lead to increased abundance of double-spliced species. In addition, 
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given the importance of RNA secondary structure in the maintenance of ME splicing in other 
systems (McManus and Graveley, 2011), a systematic analysis of endogenous RNA structure 
could be carried out, in order to find elements that might mediate ME maintenance via long-
distance base pairing.  
4.2.4 Effects of transcription and signaling pathways on PK-M splicing 
 
Recently, specific histone modifications present in genomic portions encoding PK-M exon 9 
have been reported to recruit PTB to intron 8 to repress exon 9 inclusion in HeLa cells (Luco 
et al., 2010). Since the effect of histone modifications and transcriptional elongation on ME 
splicing is relatively unexplored, experiments to determine if these factors  play a major role 
in determining M1/M2 ratios could be performed. For example, a well characterized RNA 
polymerase II elongation mutant (de la Mata et al., 2003) could be expressed in HeLa cells 
together with the minigene to see if the slower Pol II elongation mutant could affect M1/M2 
ratios. Similarly, signaling pathways have been shown to affect the activity of splicing 
factors (Blaustein et al., 2005). Since PK-M2 and signaling pathways are intimately related 
(Hitosugi et al., 2009; Yang et al., 2011), inhibition of selected pathways that are involved in 
cellular metabolism, growth and survival, for example, the mTOR, PI3K, EGFR and HGF 
pathways by widely available small-molecule inhibitors and assessing M1/M2 transcript 
ratios upon inhibition might be informative in determining which signaling pathways are 
important in the modulation of M1/M2 transcript ratios. 
4.2.5 Tissue-specific mechanisms of PK-M splicing 
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I have found that an exon 10 3’ss minigene mutant (Chapter 2) behaves differently in 
different cell lines. In HeLa (data not shown) and 293 (Fig 1A) cell lines, the %M1 upon 
transfection is small (less than 10%). However, in cell lines derived from brain and muscle 
tissue, such as the glioblastoma A172 (Fig 1B), neuroblastoma SK-N-BE2 (Fig 1C) and 
rhabdomyosarcoma A204 (Fig 1D) cell lines, the extent of PK-M1 inclusion is drastically 
increased. It seems that the switch to the use of the exon 9 3’ss upon abrogation of the exon 
10 3’ss is much more efficient in these cell lines. However, I have not begun experiments to 
find out why this is so, and this is a potentially interesting project in the future.  
4.2.6 Establishment of in vitro splicing system to find trans-acting factors involved in 
PK-M splicing 
 
A complementary approach to finding critical cis-elements is to establish in vitro splicing 
systems in a PK-M2 dominant context, such as in HeLa nuclear extracts, a fully PK-M1 
dominant context, such as the rat brain splicing extract (Grabowski, 2005) or partial PK-M1 
dominant system such as WERI-Rb1 extracts (Fig 1E). The different extracts could be mixed 
together to see if there are any changes in the M1/M2 splicing pattern, and fractionation of 
extracts could be carried out in order to isolate the factors involved in eliciting such a change. 
However, in order to establish such a system, the 6.4 kb minigene must be shortened to about 
1.5 kb. Even though the critical cis elements are found in the exons, more work needs to be 
done to isolate other important splicing elements in the introns in order to find the minimal 
set of elements that are sufficient to recapitulate endogenous splicing patterns in all systems. 
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4.3 Figures and Legends 
Figure 4.3-1 
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4.3.1 Fig 1. Unpublished data and future directions.  
 
(A), (B), (C), (D). Behavior of the exon 10 3’ss mutant minigene in different cell lines. RT-
PCR analysis of the exon 10 3’ss mutant minigene transfected in the cell lines indicated 
above, and harvested 48 hours later. % M1 is indicated at the bottom, while minigene species 
are indicated on the left in lower case, with important species in blue font. (E) Endogenous 
splicing pattern for the WERI-Rb1 retinoblastoma cell line. RT-PCR analysis of endogenous 
PK-M splicing. %M1 is indicated at the bottom, while endogenous species are indicated on 
the left in capital letters. 
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5 List of Abbreviations 
 
ASO  antisense oligonucleotide 
ATP  adenosine triphosphate 
A172  A172 human glioblastoma cells 
BPS  branch point Sequence 
cDNA  complementary DNA 
CTD  C-terminal domain of RNA polymerase II 
CLIP  Cross-linking and immunoprecipitation 
DMEM Dubelcco’s modified Eagle medium 
DNA  deoxyribonucleic acid 
dNTP  deoxynucleotide triphosphate 
Dox  doxycycline 
ECL  enhanced chemiluminescence 
EJC  exon junction complex 
ESE  exonic splicing enhancer 
ESS  exonic splicing silencer 
FBS  fetal bovine serum 
HeLa  ovarian cancer cells from Henrietta Lacks 
HEK 293 human embryonic kidney cells 
HIF1α  hypoxia inducible factor 1-alpha 
hnRNP heterogenous nuclear ribonucleoprotein 
ISE  intronic splicing enhancer  
ISS  intronic splicing silencer 
kDa   kilodalton 
MOE  2’-O-methoxyethyl  
mRNA  messenger ribonucleic acid 
MSCV  murine stem cell virus 
mTOR  mammalian target of rapamycin 
Mut  Mutant 
NMD  nonsense-mediated mRNA decay 
PCR  polymerase chain reaction 
PI3K  phosphoinositide 3-kinase 
PK-M  Pyruvate kinase M gene 
PK-M1 splicing isoform 1 of pyruvate kinase M 
PK-M2 splicing isoform 2 of pyruvate kinase M 
PMO  phosphorodiamidate morpholino oligonucleotide 
PNA  peptide nucleic acid 
Pol II  RNA polymerase II 
Poly(A) polyadenylation 
PPT  polypyrimidine tract 
PTC  premature termination codon 
RNA  ribonucleic acid 
RNAi  RNA interference 
RRM  RNA recognition motif 
RS  arginine and serine rich domain 
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SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SR  serine and arginine domain containing protein 
SRSF1  Serine and arginine rich, splicing factor 1 
SRSF3  Serine and arginine rich, splicing factor 3 
siRNA  small interfering RNAs 
snRNP  small nuclear ribonucleoprotein 
ss  splice site 
U87-MG U87-MG human glioblastoma cells 
WT  wild-type 
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